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Yuzhi Xi: U.S. Dialysis Patients and PM2.5 Exposure 
(Under the direction of David B. Richardson) 
 Ambient PM2.5 exposure is a ubiquitous pollutant that has demonstrated adverse health 
impacts in the general population. However, hemodialysis patients may be sub-population that is 
particularly susceptible adverse health impacts of ambient PM2.5 exposure. This dissertation 
examines associations between PM2.5 exposure with clinical endpoints and repeatedly measured 
biomarkers among patients receiving maintenance in-center hemodialysis.  
Using the United States Renal Data System registry, we enumerated two cohorts of adult 
hemodialysis patients for clinical endpoint analysis (2011-2016) and biomarker analysis (2008-
2014), separately. ZIP code-level ambient PM2.5 was linked to participants based on last dialysis 
clinic visited. Cardiovascular (CV) event and mortality were ascertained from USRDS. Discrete 
time hazards regression was used to estimate the effect of short- and long-term exposure. 
Biomarker measurements were ascertained from a private dialysis provider database. Mixed 
effect and generalized estimating equation models were used to estimate the association between 
short-term PM exposure and changes in repeatedly measured biomarkers. 
Among the 2011-2016 cohort (n =314,079), a 10 µg/m3 increase in the short-term PM2.5 
was associated with increased hazard rates in CV event (HR: 1.03, 95% CI: 1.02, 1.04), CVD-
specific mortality (1.05, 95% CI: 1.03, 1.08), and all-cause mortality (1.04, 95% CI: 1.03, 1.06); 
a 1 µg/m3 increase in annual-average PM2.5 was associated with increased HRs in CV event 





specific mortality (1.015, 95% CI: 1.009, 1.021). The effects were more pronounced for patients 
who initiated dialysis at an older age. Among the 2008-2014 cohort (n = 173,697), every 10 
µg/m3 increase in same-day PM2.5 was associated with increased relative risk of low albumin 
(RR: 1.012, 95%CI: 1.008, 1.016), high ferritin (1.041, 95%CI: 0.990, 1.093), low hemoglobin 
(1.008, 95%CI: 1.004, 1.011), increase in transferrin saturation, and decreases in pre-dialysis 
blood pressures. 
Short- and long- term ambient PM2.5 exposure were associated with elevated 
cardiovascular and mortality risk among HD patients, and patients with advanced age and COPD 
appeared to be more susceptible. Short-term exposure to PM2.5 was associated with changes in 
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CHAPTER 1. SPECIFIC AIMS 
 Particulate matter with aero-diameter of 2.5 micrometer (PM2.5) or smaller is one of the 
six criteria ambient pollutants regulated by US Environmental Protection Agency (EPA) under 
the Clean Air Act. The fine size of PM2.5 allows it to get deep into lungs, and even the 
bloodstream. Previous studies have linked PM2.5 exposure with cardiovascular diseases (CVD), 
respiratory conditions, and overall mortality in the general population.(1-3) It is also known that 
there are potentially sensitive/susceptible populations including children, the elderly, and people 
with pre-existing diseases who are the more likely to be negatively affected by PM exposure.(1, 
3)  
 Since March 18, 2013, the National Ambient Air Quality Standard for PM2.5 has been 
updated to 35 g/m3 and 12 g/m3 for 24-hour and annual averages, respectively. Currently, for 
most of the US, the daily PM2.5 level is well below the daily standard, and since 2012, the US 
annual PM2.5 averages have been maintained below this latest annual standard.(4) However, it is 
unclear if exposures below-regulation-standard is safe, particularly for those potential 
sensitive/susceptible populations. In addition, some highly-populated regions still experience 
high PM2.5 and extreme events like wildfires also generate extreme high level of ambient PM2.5. 
Recent study by Qi et al., using the Medicare population for the years 2000-2012, demonstrated 
that exposure to PM2.5 at levels below current standards is associated with increased risk of 
mortality among elderly population (aged 65 or over).(5) It is suggested that the current US 
PM2.5 levels, which typically are below regulation standard, may not be safe for the elderly.(5) 





evidence for regional and personal-level exposure mitigation. Furthermore, sensitive or 
susceptible populations should be identified and studied to understand their needs and promote 
health. 
 In the US, kidney failure patients who are on maintenance in-center hemodialysis (HD) 
are a large and growing potentially susceptible population, among whom the effect of PM2.5 
exposure is unknown, and rarely studied. Based on the latest United States Renal Data System 
(USRDS) 2015 Annual Report, about 500,000 US patients were receiving in-center 
hemodialysis.(6) This number is predicted to increase steadily in the next decades with high 
prevalence of diabetes and obesity, and aging population and inadequate organ sources for 
transplant. Dialysis patients are fragile with multiple pre-existing conditions. Specifically, their 
emergency department (ED) visit rate is 6 times higher than the general population, which puts 
great burden on dialysis patients and the health care system.(7) They are also known to have 
elevated cardiovascular (CVD) risks. In this population, mortality due to CVD is several times 
higher than that in the general population.(8, 9) Weng et al. found that higher ambient 
concertation of PM is associated with an elevated magnitude of aortic pulse wave velocity 
(PWV), which is an independent predictor of CVD mortality.(10) Feng et al. also observed an 
increase risk in all-cause mortality among kidney failure patients receiving both peritoneal 
dialysis and hemodialysis.(11) 
 The dissertation aimed to assess the health impacts of PM2.5 exposure among US HD 
patients. Specifically, the first aim assessed the short-term PM2.5 exposure effect, the second aim 
focused on the effect of long-term PM2.5 exposure, and the third aim addressed pathological 
mechanisms of PM2.5 for this potentially susceptible population assessing the short-term 





of HD patients will be identified from the United States Renal Data System (USRDS) database. 
Follow-up will start at the initiation of HD treatment and end at Dec 31, 2016 for Aim 1 and 2, 
and Dec 31, 2014 for Aim 3, outcome of interests, loss of Medicare coverage, or change of 
treatment modality. Their baseline characteristics and clinical modality including dialysis clinic 
visits, emergency department (ED) visits, and hospitalization will be extracted from USRDS 
claims. For the last aim looking at the potential biological mechanisms, regular measurements of 
a subgroup of the cohort will be extracted from the DaVita Clinical Research database. The daily 
PM2.5 exposure will be estimated using previously published model on the ZIP code-level. The 
exposure measurement will be linked to each included patient using their dialysis clinic 
addresses. 
Aim 1. Assess the association between all-sourced PM2.5 short-term exposure with mortality 
and cardiovascular (CV) events among USRDS cohort 2011-2016.  
1.a. Assess the association between short-term PM2.5 exposure with all-cause and CVD-specific 
mortality. The cause of death will be retrieved from CMS 2746 Form. 
1.b. Assess the association between short-term PM2.5 exposure and CV event defined as first 
CVD related ED visits, hospitalization, or CVD related mortality. ICD-9 and -10 codes 
associated with each ED visit and HA will be used to identify CV events.  
1.c. Assess the potential modification of above associations by age, race, gender, and 
comorbidities status. The baseline characteristics recorded in from CMS 2728 will be used as the 
potential modifiers. 
Aim 2. Assess the association between all-sourced PM2.5 long-term exposure with mortality 
and CV events among USRDS cohort 2011-2016. Long-term PM2.5 is defined as PM exposure 





2.a. Assess the association between long-term PM2.5 exposure with all-cause and CVD-specific 
mortality. The cause of death will be retrieved from CMS 2746 Form. 
2.b. Assess the association between long-term PM2.5 exposure and CV event defined as first 
CVD related ED visits, hospitalization, or CVD related mortality. ICD-9 and -10 codes 
associated with each ED visit and HA will be used to identify CV events.  
2.c. Assess the potential modification of above associations by age, race, gender, and 
comorbidities status. The baseline characteristics recorded in from CMS 2728 will be used as the 
potential modifiers. 
Aim 3. Assess the association between all sourced PM2.5 short-term exposure and regular 
lab measurements among subgroup DaVita cohort 2008-2014. This aim will be assessed 
within the cohort subgroup of DaVita population with regular lab measurements information 
available. A longitudinal analysis will be performed. Those lab measurements include indicators 
for nutrition, inflammation, and overall health conditions for dialysis patients.(12, 13) 
3.a. Assess the short-term PM2.5 exposure and serum ferritin, albumin, serum hemoglobin, 
transferrin saturation (TSAT), and blood pressures. 
3.b. Assess the lagged short-term PM2.5 exposure and serum ferritin, albumin, serum 







CHAPTER 2. BACKGROUND AND SIGNIFICANCE 
 Particulate matter with an aero-diameter less than 2.5 m (PM2.5), is one of the six 
criteria ambient pollutants regulated by the United States Environmental Protection Agency 
(EPA) for its established adverse health impacts in general populations.(1) Currently, ambient 
PM2.5 concentration is below the regulation standard for the most parts of U.S. However, recent 
studies suggest even at low levels, PM2.5 exposure is still associated with elevated risk of adverse 
health outcomes. Particularly, for vulnerable populations, the below-standard PM2.5 exposure can 
still pose threats to health. Thus, the aim of this dissertation is to assess the current U.S. ambient 
PM2.5 exposure’s impact on health among an under-studied potential susceptible population of 
end stage renal disease (ESRD) patients who are relying on maintenance hemodialysis treatment. 
PM2.5 Exposure 
 Humans have encountered PM2.5 since the start of human history. However, it was only 
recently, about 70 years ago, that researchers started to understand that particulate matter 
exposure can lead to adverse health outcomes through extreme events like the well-known 1952 
Great London Smog that led to 4,000 more than usual deaths in a five-day period.(14) Increased 
air pollution has been a harsh consequence of industrialization and modernization across the 
world as the byproduct of fossil fuel discovery. Since then, research and management effort have 
been carried out continuously in attempt to understand and mediate the health risk associated 





 Particulate matter often is a complex mixture of solid and liquid droplets that are 
characterized by distinct size fraction (i.e., PM2.5 and PM10). For the purpose of this dissertation, 
PM2.5 will be the primary exposure of interest for its finer size and its established adverse health 
impact.(3) PM2.5 is comprised of components that are directly emitted (primary) as well as 
formed through atmospheric chemical reactions involving gaseous precursors (secondary). The 
dominant primary particle source for PM2.5 is combustion of fossil fuels and biomass in addition 
to high temperature processes. The secondary PM2.5 formation processes include partitioning of 
gas phase products of precursor oxidation and aqueous oxidation of dissolved precursors with 
evaporation and growth cycling.(1) The typical chemical components of PM2.5 are sulfate, 
nitrate, ammonium, hydrogen ions, elemental carbon, low and moderate volatility organic 
compounds, and metals. 
 Primary PM2.5 can be emitted from both natural and anthropogenic sources. The US 
national PM2.5 emission is estimated to be 5,400,000 tons per year based on the 2014 US EPA 
National Emission Inventory.(15) On the national level, the major contributors to primary PM2.5 
are agricultural dust, dust re-suspended through on-road activities, fires (i.e., wildfires, 
prescribed fires), and fuel combustions, which account for 19%, 13%, 32%, and 6% of the total 
national emission, respectively.(1) On a national scale, anthropogenic emissions (emission due to 
human activity) have been estimated to account for 40% of total primary PM2.5 emissions.(1, 15) 
 Secondary PM2.5 is generated by secondary formation of precursors through various 
chemical reactions. NOx (nitrogen oxides), VOC (volatile organic compounds), SO2 (sulfur 
dioxide), NH3 (ammonia), and ozone are the major precursors for secondary PM2.5. NOx is 
emitted by a range of combustion sources, including lists of mobile sources.(1) VOCs are 





petroleum refining et al.(1) SO2 are mainly emitted from electricity generating units (i.e. coal 
power plan).(1) Ammonia emissions are primarily generated by livestock waste from animal 
husbandry operations and fertilizer application. NOx compounds transform into PM2.5 as 
particulate nitrates in the presence of ozone; VOC become particulate organic carbon in the 
presence of ozone; SO2 transform to sulfate, and NH3 become particulate ammonium.(1) The 
portion of all PM2.5 comprised of all secondary components (sulfates, nitrates, ammonium, 
organic carbon) varies anywhere from 30% to 90%. The percentage of PM2.5 from VOC 
precursors varies from approximately 11% to 41%.(1) The percentage of PM2.5 formed from 
NOx precursors varies from approximately 4% to 37%. PM2.5 generated from SO2 accounts for 
7% to 47% of total PM2.5. The percentage of PM2.5 generated from NH3 accounts for 3% to 20% 
of the total PM2.5.(1) 
 
Figure 2-1. US PM2.5 Concentration 2000-2018 Trend (4) 
Primary and secondary PM2.5 exists in the ambient environment as a mixture, and, in 
general, PM2.5 ambient concentration is managed as the total mass of this mixture per unit of 
space. The commonly used unit for PM2.5 concentration is g/m3. In the US, PM2.5 is managed as 





the Clean Air Act. Since March 18, 2013, EPA has stringent the National Ambient Air Quality 
Standard for PM2.5 to be 35 g/m3 and 12 g/m3 for 24-hour and annual averages, respectively. 
US PM2.5 concentrations have decreased considerably over the past decades. Since the year of 
2012, the US average PM2.5 concentration has dropped below the national standard with a 39% 
decrease in national annual average from 2000 to 2018. (Figure 2-1) (4) According to the latest 
Integrated Science Assessment (ISA) for Particulate Matter, the 24-hour average PM2.5 
concentration was 8.5 g/m3 and the annual mean concentration was 8.6 g/m3 2013-2015, 
which are both below the current regulation standards.(4) These levels are projected to keep 
reducing gradually. For the most part of U.S., the current ambient PM2.5 concentration is well-
managed and lower than the regulatory standards.  
 However, PM2.5 concentration varies both spatially and temporally. For example, in some 
highly populated metropolitan areas like Los Angeles-South Coast Air Basin, San Joaquin 
Valley, Ohio Valley, and Eastern Pennsylvania, the annual average PM2.5 concentrations were 
above or near the regulation limit.(4) In addition, seasonal and occasional weather events can 
impact the local PM2.5 concentration significantly. Some of the California regions experience 
daily PM2.5 level as high as 270.1 g/m3 due to the smoke plume generate by wildland fires 
burning nearby during wildfire seasons.(1) In most of time for most part of U.S., the ambient 
PM2.5 levels are below the regulation standard, but variation exist across different regions and 
seasons. 
Health Effects of PM2.5 
 Individuals are exposed to ambient PM2.5 particles primarily via inhalation. With its fine 
size, once inhaled, PM2.5 can travel deep into the respiratory tract and enter the bloodstream 





epidemiological studies of PM2.5 exposure’s health impacts, ambient PM2.5 concentration is often 
used as the surrogate for individual exposure. Individual PM2.5 exposure is determined by both 
environmental and behavioral factors.(16) The environmental factors include ambient PM2.5 
concentration and indoor/outdoor air filtration efficiency. Behavioral factors include time spent 
outdoor/indoor, smoking behavior, physical activity level, occupation and cooking behavior. 
Studies suggested that the outdoor ambient PM2.5 concentration is the dominant predictor of and 
the largest contributor to personal exposures (both indoor and outdoor) for PM2.5 masses and 
compositions, and other factors will have impacts on the correlation between ambient PM2.5 and 
individual exposure levels.(16-20) 
 The effect of PM2.5 is governed by particle dosimetry which is the characterization of 
deposition, translocation, clearance, and retention of particles and their components within the 
respiratory tract and extra-pulmonary tissues. The dose from inhaled particles deposited and 
retained in the respiratory tract is determined by many factors: exposure concentration and 
duration, activity and breathing conditions (e.g., nasal vs. oronasal route and minute 
ventilations), and particle properties (e.g., particle size, hygroscopicity, and solubility in airway 
fluids and cellular components).(4) Individual-level factors like age, sex, body mass index, and 
health conditions (e.g. respiratory tract disease status) that determine the individual’s breathing 
patterns and route of breathing will ultimately affect the amount of PM that entered, deposited at, 
and cleared out from the body, which could ultimately lead to between-individual variation in 
health effect under the same ambient environment. For instance, in adults at rest, the nasal 
deposition of PM2.5 is about 20% and increases to 30-40% during exercise. Nasal deposition in 
children 5-15 years old is lower (10-20%).(21) Once deposited in the lung, most particles are 





ciliated airways are generally removed from the respiratory tract by mucociliary activity within 
days.(22) The clearance from the pulmonary region may occur through the action of alveolar 
macrophages within weeks.(22) Therefore, when studying ambient PM2.5 exposure’s health 
impact, those factors effecting individual exposure level and the dosimetry of PM2.5 can 
potentially modify the association under assessment. 
 Previous studies have linked PM2.5 exposure to pathological mechanisms including 
inflammation (both local and systematic), oxidative stress, cell autophagy, and cell apoptosis, 
which could results in clinical outcomes like CVD disease and eventually mortality.(23-28) 
Inflammation is one of the most studied potential mechanisms for particulate matter exposure. A 
study among the Study of Women’s Health Across the Nation observed a significant association 
between PM2.5 exposure and C-reactive protein (CRP), an established marker of 
inflammation.(29) A recent study observed that PM2.5 particles induces inflammatory response in 
macrophages, which plays a key role in response to foreign irritants in the lung.(30) Another 
study among the Framingham Heart Study cohort observed that elevated short-term exposure to 
relatively low levels of PM2.5 was associated with increased levels of systematic inflammation 
markers including C-reactive protein, interleukin-6, and tumor necrosis factor receptor 2.(31) 
Specifically, they found that a 5 µg/m3 increase in 5-day moving average PM2.5 was associated 
with 4.2% (95% CI: 0.8, 7.6) higher circulating CRP.(31) In-vivo, in-vitro and animal studies 
have also found evidence for PM2.5 induced inflammation responses, however, the exact 
pathological mechanism of ambient PM2.5 remains not fully understood.(3) 
 Studies have linked ambient PM2.5 exposure with a range of adverse health outcomes, 
including respiratory diseases, cardiovascular (CVD) diseases, nervous system conditions, 





dissertation, this following section focused on two major outcomes of mortality and 
cardiovascular endpoints, which will be the primary interests of outcomes of this dissertation. In 
addition, several susceptible populations with potential elevated risk for PM2.5-related health 
impact that been suggested by literature will be described in this the following section. 
Mortality 
 Studies have linked both short-term and long-term PM2.5 exposure with non-accidental 
mortality. The latest 2019 Integrated Science Assessment for Particulate Matter (PM ISA) 
concluded that “a causal relationship exists between short-term exposure to PM2.5 and 
mortality”.(1, 3) This conclusion was based on the evaluation of both multi-and single-city 
studies, and the associations were strongest primarily at the same day of exposure or at lag of 0-1 
days.(4) Recent multicity studies primarily report consistent positive associations for short-term 
PM2.5 exposure and total mortality. The effect sizes of short-term PM2.5 exposure on total (non-
accidental) mortality range from 0.19% to 2.80% for every 10 g/m3 increase in daily PM2.5.(32, 
33) Studies have also assessed the shot-term exposure effect on cause-specific mortality. In 
general, studies yield more homogenous results for respiratory mortality than for cardiovascular 
mortality.(1, 34) Due to the mixed results for cause-specific mortality reported in literature, more 
studies are needed to make the conclusion that short-term PM2.5 exposure is causally related to 
respiratory, cardiovascular or other cause-specific mortality. 
 For the association of long-term PM2.5 exposure and mortality, the 2019 PM ISA 
summarized that the evidence was “sufficient to conclude that the relationship between long-
term PM2.5 and mortality is causal”.(3) This conclusion was draw based on results from two 
seminal cohort studies, the American Cancer Society and the Harvard Six Cities studies.(35, 36) 





studies suggesting that there is an association between long-term PM2.5 and total mortality.(37-
40) It is noteworthy that the effects size varies within study by different exposure assessment 
applied.(1, 41) Long-term PM2.5 exposure’s impact on cause-specific mortality have also been 
assessed in recent studies, but the results are mixed and inconclusive in terms of causal 
inference. It is noteworthy that most studies ascertained the long-term exposure as the annual 
average ambient PM2.5 level, which is simple and comparable to the national annual standard. 
Cardiovascular Outcomes 
 Studies have linked both short-term and long-term PM2.5 exposure with ranges of 
cardiovascular outcomes. In this section, the short-term and long-term cardiovascular effect of 
PM2.5 exposure will be discussed separately.  
 The 2019 PM ISA concluded that “a causal relationship exists between short-term 
exposure to PM2.5 and cardiovascular effects”.(3) This conclusion was drawn based on multiple 
lines of evidence including consistently positive associations between short-term exposure to 
PM2.5 and emergency department (ED) visits and hospital admission for cardiovascular disease 
by epidemiological studies.(42, 43) These observed effects were supported by changes in 
different measures of cardiovascular function in response to PM2.5 exposure identified in 
controlled human exposure and animal toxicological studies.(1) Since 2009, more epidemiologic 
studies demonstrate a clear relationship between short-term PM2.5 exposure and cardiovascular 
outcomes of ED visits and hospital admissions for ischemic heart disease (IHD) and heart failure 
(HF).(44, 45) Studies also assessed PM2.5-related cardiovascular effects for other specific 
cardiovascular (CVD) endpoints including arrhythmia, cardiac arrest, cerebrovascular disease, 
stroke, hypertension, and peripheral vascular disease, and the results are more mixed for those 





epidemiologic studies also studied the combined CVD effects by aggregating multiple specific 
conditions related ED visits and hospital admission in analyses which provide more statistical 
power by pooling individual endpoints together. 
 Additionally, the 2019 PM ISA concludes that the scientific evidence pertaining to the 
cardiovascular health effects of long-term PM2.5 exposure was “sufficient to infer a causal 
relationship between long-term PM2.5 exposure and cardiovascular effects”.(3) Since then, more 
recent epidemiologic studies add to the evidence base supporting the association of long-term 
exposure to PM2.5 and cardiovascular effect. Recent large cohort studies have linked PM2.5 
exposure with a list of cardiovascular endpoints: ischemic heart disease (IHD)/ coronary artery 
disease (CAD)/ coronary heart disease (CHD), myocardial infarction (MI), heart failure, and 
cerebrovascular disease (including stroke).(45, 48, 49) 
Susceptible Populations 
 Several susceptible populations to PM2.5 exposure have been suggested by previous 
research. Here susceptible populations refer to the populations that have a higher risk of 
experiencing PM2.5-related health impacts compared to the general population when exposed. It 
is important to identify susceptible populations towards PM2.5 exposure to inform intervention 
development and regulations, which ultimately will promote health not only for those susceptible 
individuals but also for the general population.  
 In epidemiology studies of PM’s health impact, susceptible populations are usually 
identified through subgroup analysis stratified by potential effect measure modifiers. 
Specifically, studies suggested that people with pre-existing diseases may be at increased risk for 
PM2.5 related health effects comparing to the general population.(1, 3) For example, studies 





be at increased risk for PM2.5 related health effects compared to those without a pre-existing 
cardiovascular disease.(50, 51) Respiratory disease and obesity were also linked with elevated 
risk for PM2.5 exposure-related health impacts.(52-55) Additional pre-existing conditions have 
been studied as potential modifiers are diabetes and elevated cholesterol, but the results are 
mixed for those conditions.(39, 56) Besides population with pre-existing conditions, other 
suggested susceptible population are nonwhite race groups, children, and low social economic 
status populations. Children are particularly at risk for health effects related to ambient PM2.5 
exposure compared to adults due to their respiratory system is not fully developed and their 
breathing patterns increase the among of ambient PM2.5 inhaled. Studies observed strong(-er) 
PM2.5-related respiratory effects in children.(57) For nonwhite population and population with 
low social economic status, elevated risk of health impact associated with PM2.5 has been 
observed, and studies suggested that the disparity in exposure could play a role in the elevated 
risk experienced by these populations.(54, 55, 58, 59) Previous studies also indicated that PM2.5-
related health risk could be elevated among older adults, males, current smokers, and those who 
reside near road or in urban areas, but the evidence is mixed and inconclusive.(1, 3)  
Health Impacts at Low Concentrations 
 Recent studies highlight the fact that even at low concentrations (levels at or below the 
regulatory standard) ambient PM2.5 exposure is still associated with elevated risk of mortality 
and other adverse health outcomes. Health impact of low-level PM2.5 exposure was observed 
across different cohorts. A study by Qi et al. among the Medicare population (aged over 65), 
which account for 15% of total United States population, demonstrated that exposure to PM2.5 at 
levels below current standards (mean 24 hour average PM2.5= 12.4 g/m3) is associated with 





study by Pope et al. with the ACS cohort observed cardiovascular and respiratory effects of 
PM2.5 at low levels (mean PM2.5= 12.6 g/m3).(60) Hart et al. found a similar positive 
association between low-level PM2.5 (mean= 12.0 g/m3) exposure and all-cause mortality 
among the Nurses’ Health Study cohort.(61) Multiple systematic reviews and meta-analyses also 
conclude that there are significant health effects associated with low-level PM2.5 exposures.(62-
64) Particularly, for vulnerable or susceptible populations, the well-managed U.S. ambient PM2.5 
could still pose a threat to health.  
Plausible Biological Mechanisms 
 Due to its fine size, PM2.5 inhaled can penetrate deep down into lung and reach 
bloodstream without being filtered. In a polluted environment, over a 24-hour period, each lung 
acinus could receive approximately 30 million particles and each alveolus 1500 particles.(65) 
Lung airways and alveoli retain about 50% of these particles which are primarily PM2.5.(65) In-
vivo study reported that PM2.5 accounts for 96% of particles observed in human pulmonary 
parenchyma.(66) 
 The exact mechanisms underlying PM2.5-related health effect have not been fully 
elucidated. Several pathways have been hypothesized.(23) First of all, inflammation has been 
shown to be involved in most of the adverse health effect of PM2.5.(23) In vitro, PM2.5 has been 
shown to induce inflammatory responses in various human and animal cells like increases in pro-
inflammatory mediators.(67-69) In vivo, PM2.5 has also been shown to trigger in local and 
systemic inflammation.(70, 71) PM2.5 has been linked to increase inflammatory response in 
different target organs, such as lung, liver, spleen, kidney and heart. Systematic inflammation 
related to PM2.5 exposure have been demonstrated with elevated level of inflammation 





protein, oxidized low-density lipoproteins, interleukin 6 (IL-6), and vascular endothelial growth 
factor in the blood.(23) Second, PM2.5-induced oxidative stress has also been considered as 
another potential mechanism of PM2.5 toxicities. Studies have shown that PM2.5 exposure may 
contribute to systemic oxidative stress and damages in human or animal cells through production 
or elevation of intracellular reactive oxygen species and impairment of antioxidant capacity of 
exposed cells.(24, 25, 72, 73) Third, PM2.5 exposure related to alternation of immune function is 
also suggested as one mechanism that contributes to the overall adverse health impacts observed 
in population studies.(1)  
 For PM2.5 exposure’s cardiovascular effect, plausible biological mechanisms have also 
been studied, but remain to be fully elucidated. In summary, current literature suggests PM2.5 
exposure could lead to cardiovascular endpoints through three major pathways.(74) The current 
understanding of plausible biological mechanisms for PM2.5 triggering cardiovascular outcomes 
is summarized in Figure 2-2. In the first pathway, PM2.5 particles could translocate into the 
pulmonary circulation and the systemic circulation, where it can cause direct cardiovascular 
dysfunction through reactive oxygen species production and regulation of calcium levels.(74-76) 
The second pathway begins as PM2.5-triggered respiratory tract inflammation leading to systemic 
inflammation which in turn activates hemostatic pathways, impairs vascular function, and 
accelerates atherosclerosis.(74, 77, 78) The third pathway involves activation of sensory nerve 
pathways in the respiratory tract which will lead to modulation of the autonomic nervous 
system.(74, 79) The autonomic nervous system has a key role in the control of heart rate and 
heart rate variability, which are predictors of cardiac death in HF. Once these pathways are 





cardiovascular events such as IHD and HF, which require ED visits and hospital admissions and 
could ultimately lead to mortality. 
 
Figure 2-2. Biological mechanisms of PM2.5 exposure leading cardiovascular outcomes (80) 
Despite this evidence, more studies are still needed to disentangle the plausible pathology 
of PM2.5. Understanding the biological mechanisms of PM2.5 related toxicity is the key for 
clinical intervention development to stop or reverse the damaging impact. Based on the existing 
literature, inflammation is one of the predominant and wildly supported hypothesis of PM2.5 
triggered mechanisms for both general health outcome and cardiovascular specific endpoints. 
Thus, to understand the biological mechanism of PM2.5 toxicity, inflammation related biomarkers 
or endpoints should be evaluated and studied as one of the potential research directions.  
Dialysis Patients 
 End stage renal disease (ESRD) patients who undergo in-center maintenance 
hemodialysis treatment is a large and keep growing potential susceptible population towards 





disease. (It worth noting that the terminology “ESRD” or “end stage renal disease” is phasing out 
of the clinical application and literature. However, at the time of composing this document, most 
of the previous literature were still using this terminology. Thus, this phrase will be used in this 
chapter of this document, but in later chapters describing the findings of this project, “kidney 
failure” will be used instead). At this stage, the patients’ kidneys are only functioning at 10 to 15 
percent of their normal capacity. Based on the latest, 2018 United State Renal Data System 
(USRDS) Annual Data Report, there were 124,675 newly reported ESRD cases for the year of 
2016, which contribute to the overall 726,331 prevalent ESRD cases in the U.S..(6) The crude 
prevalence for ESRD was 2,160.7 per million in the U.S. population. In addition, the number of 
prevalent ESRD cases has continue to rise by about 20,000 cases per year.(6) Among those 
ESRD patients, 63.1% of all prevalent ESRD patients were receiving hemodialysis (HD) 
treatment, 7.0% were treated with peritoneal dialysis (PD), and 29.6% had a functioning kidney 
transplant (Figure 2-3). Among HD cases, 98% used in-center HD, and 2.0% used home HD. 
Thus, in the U.S. about 500,000 ESRD patients are receiving in-center hemodialysis currently. 
This number is projected to keep rising because of high rates of obesity and diabetes, an aging 
population, and a scarcity of organs for kidney transplantation.(80) 
 






Among U.S. ESRD patients, compared to Whites, ESRD prevalence is about 9.5 times 
greater in Native Hawaiians/Pacific Islanders, 3.7 times greater in Blacks, 1.5 times greater in 
American Indians/Alaska Natives, and 1.3 time greater in Asians. Among different age groups, 
ESRD prevalence is highest in the oldest groups 65 years old or above. Over time, U.S. ESRD 
prevalence ESRD prevalence has increased, and a steeper increase among the older age groups 
has been observed.  
 Dialysis populations are known to have a  high prevalence of multiple comorbidities in 
addition to end stage renal disease.(9, 81, 82) A recent study of U.S. dialysis patients reported 
that 62.8% of all hemodialysis patients are diabetic, 34.2% have experienced congestive heart 
failure, 25.4% have coronary artery disease, 11.1% have cerebrovascular disease, and 14.8% of 
them have peripheral vascular disease, at the initiation of dialysis.(82) It is also reported that the 
comorbidity prevalence keeps increasing as dialysis patients continuously develop morbidities 
while they receive dialysis treatment for a longer period of time.(81) Specifically, this population 
are known to have higher rates of cardiovascular comorbidity and reduced survival in 
comparison to the general population.(83, 84) CVD is the major cause of morbidity and mortality 
among ESRD patients on hemodialysis. In this population, mortality due to CVD is 20 times 
higher than that in the general population.(8) Hypertension and diabetes mellitus are the two 
major causes of renal failure, the elevated CVD risk in HD patients has been assumed to be the 
result of these pre-existing conditions. Prior studies have also elucidated that kidney failure itself 
presents a CVD risk factor in addition to hypertension and diabetes mellitus.(85, 86) 
Furthermore, despite the overall slowly declining trends in recent years, dialysis patients still 
experience a high annual mortality rate of 16% based on USRDS annual report.(6) For HD 





vintage (time since dialysis initiation) is reported to be around 4 years.(87) Dialysis patients’ life 
expectancy are also significantly shorter when compared to that of the general population. For 
ESRD patients who are 60-64 years old and undergo dialysis treatment, their expected remaining 
lifetime is 6.7 and 6.6 years comparing to that of 19.9 and 22.7 years for general U.S. population 
of the same age group for male and female, respectively.(6) Dialysis patients’ emergency 
department (ED) visit rate is also 6 times higher than the general population, which puts great 
burden on those patients and the health care system.(7) Thus, any effort to reduce the health 
burden and promote health in this population will have a significant impact. 
Due to their frailty and the need for treatment effect monitoring, HD patients’ health 
conditions are closely monitored by frequent measurements of a variety of biomarkers at the 
dialysis center before, during or after dialysis session. Among all of the biomarkers frequently 
measured among this population, a group of markers for their correlation with health outcomes, 
linkage to PM exposure, and availability were identified for this project to understand the 
potential pathological mechanism of PM2.5 exposure. Serum albumin level is an important index 
for assessing nutritional status and treatment effect of dialysis patients, low serum albumin is 
indicator for inflammation, infection, and other conditions.(88, 89) Serum ferritin is also closely 
monitored among HD patients, and it is an iron storage protein, and high serum ferritin level has 
been linked to inflammation.(30, 90-92) Transferrin saturation (TSAT) is a marker of iron 
availability for erythropoiesis, and low TSAT indicates iron deficiency which is prevalent among 
dialysis patients.(93, 94) Hemoglobin (low) is an indicator for anemia, and previous studies have 
linked anemia with PM exposure in different populations.(95-97) Blood pressure is closely 
monitored before, during, and after dialysis session for HD patients, and previous studies have 





Dialysis Patients and PM2.5 
 Dialysis patients are potentially susceptible towards PM exposure due to their frailty with 
multiple pre-exiting conditions and high prevalence of inflammation.(100, 101) Currently, 
limited number of studies assessed the general environmental exposure-related health impacts 
among dialysis patients, and even fewer specifically focusing on PM2.5 exposure. Only a few 
large scale studies have been conducted among dialysis patients. Our previously published 
studies have observed that elevated exposure to wildfire generated PM2.5 is associated with 
elevated risk in all-cause mortality among US hemodialysis patients 2008-2014.(102) In a 
retrospective time-series analysis, we found a 4% increase in daily all-cause mortality (Rate 
Ratio: 1.04, 95%CI: 1.01, 1.07) per 10 µg/m3 increase in wildfire-PM2.5 and a 7% increase in 
mortality over 30 days following exposure (RR=1.07; 1.02, 1.12).(102) On days with wildfire-
PM2.5 greater than 10 µg/m3, fires accounted for 8.4% of daily mortality.(102) In addition to 
mortality, we also observed an elevated CVD hospitalization and county-level PM2.5 exposure 
among hemodialysis patients for the same-day PM2.5 exposure.(103) Wyatt et al. reported a 0.9% 
(95% CI, 0.4, 1.8%) increase in hospital admission risk for cardiovascular causes for the same-
day PM2.5 exposure.(103) Recently, a study demonstrated an elevated risk of all-cause mortality 
associated with long-term (annual average) PM2.5 among older (over 65-year old) US 
hemodialysis and peritoneal dialysis patients.(11) Their study reported that for very 10 µg/m3 
increase in annual average PM2.5 exposure below 12 µg/m3, there is a 1-5% increase in the HR of 
all-cause mortality, a similar range to our findings.(11)  
 Furthermore, several studies limited to small sample size, short follow-up period, and 
studying area of single or small geographic region have been conducted. A study by Weng et al. 





syndrome (CTS) among a group of 886 hemodialysis patients from 3 dialysis center in Taiwan, 
and suggested a positive association with this cross-section analysis.(104) This study proposed 
that CTS is linked with PM2.5 exposure as CTS is caused by the deposition of β2-
microglobulin in the carpal tunnel induced by reactive inflammation, and PM2.5 exposure have 
been significantly associated with the elevation of systemic inflammatory markers.(104-107) In 
details, their multivariate logistic regression suggested that together with either 24- or 48-month 
ambient PM2.5, hypoalbuminemia (albumin <4 g/dl), HD duration, and the normalized protein 
catabolic rate were positively associated the CTS.(104) In this study, the previous 12-month 
ambient PM2.5 was used as the exposure and the average level was 29.95 g/m3. 
 The same group of researchers also conducted a cross-sectional study on the association 
between particulate matter concentrations and aortic pulse wave velocity (PWV) among 127 
hemodialysis patients treated at one outpatients HD center in Taiwan.(10) Aortic pulse wave 
velocity has been shown to be an independent predictor of cardiovascular mortality in ESRD 
patients and the general population. In this study brachial-ankle pulse wave velocity (baPWV) 
was measured as arterial stiffness.(10) The results suggest that 12-month average ambient PM10 
level, together with systolic blood pressure (SBP), serum aluminum level and age was positively 
correlated with baPWV, suggesting that particulate matter exposure is likely to be linked to 
cardiovascular risks by affecting arterial stiffness in this population.(10) For this study, the 
annual average PM2.5 was used as the primary exposure matrix and the mean value was 31.8 
g/m3.  
Liu et al. assessed the association between the number of days of high mean 24-hour 
PM2.5 level and uremic pruritus among a group of 866 ESRD patients undergoing maintenance 





pruritus is a common and disabling symptom for hemodialysis patients. With a multivariate 
logistic regression model, this study found that together with serum ferritin levels, HD duration, 
low-density lipoprotein levels, 116 days of mean 24-hour PM2.5 over 35 g/m3 per 12 months 
were positively associated with uremic pruritus.(108) 
 Two additional studies have assessed the particulate matter exposure related health 
impact among ESRD patients: one among peritoneal dialysis (PD) patients and the other among 
non-dialysis stage five chronic kidney disease patients. With a group of 175 peritoneal dialysis 
patients in Taiwan, Huang et al. found that PD patients with high environmental PM2.5 exposure 
had a higher 1-year PD-related infection rate than that in those with low exposure with a 
retrospective survival study.(109) The more recent case-crossover study by Chiu et al. with 317 
CKD Stage 5 patients residing in central Taiwan suggested that a high ambient PM2.5 level was 
associated with an increased risk of acute lung edema.(110) In addition, they found that high 
ambient temperature in hot seasons and low ambient temperature in cold seasons were associated 
with increased risk as well.(110) 
 These studies suggest that PM2.5 exposure is potentially linked with adverse health 
outcomes among kidney failure patients. However, these published studies are limited by small 
sample size (less than 1,000), single geographic region (all conducted in Taiwan, a rather small 
geographic area with highly homogenous population construction), and non- or short follow up 
periods (mostly cross-sectional studies, and two studies with 1 year follow-up period). Therefore, 
the published results have limited internal and external validities. Also, these studies were all 
conducted in Taiwan, a highly-populated region with higher PM2.5 (annual average around 30 
g/m3). Therefore, there are limited conclusions we can draw from these studies on the health 





limited published study assessed the association between ambient PM2.5 exposure and adverse 
health outcome among a large group of kidney failure patients receiving hemodialysis in a large 
geographic region across a relatively long (multiple years) period of time at the lower levels. 
Significance 
 Despite the wealth literature on the health impact of ambient PM2.5 exposure among the 
general population, the impact to susceptible populations has not been fully studied. In addition, 
most of the previous studies studied the health effect of PM2.5 at a higher concentration, but 
currently, the vast majority of the U.S. population is exposed to ambient PM2.5 at a relatively low 
level. Lowering of PM2.5 levels have been observed in multiple countries and regions across the 
globe as a result of improvements in awareness and management. Thus, there is a gap and need 
of knowledge of how low-level PM2.5 exposures impact health, especially among susceptible 
population. Furthermore, the biological mechanisms of PM2.5 are not fully understood, which is 
critical to develop potential clinical intervention to mediate PM2.5 toxicity. 
 This dissertation focuses on a potentially susceptible population, patients undergoing in-
center maintenance hemodialysis. This is a large and keep growing population that has not been 
fully studied for PM2.5 exposure’s health impacts. The study period of this dissertation, 2008-
2016, is the period of time U.S. national PM2.5 ambient concentration dropping below the latest 
national standard. Therefore, understanding the PM2.5-exposure related health impact among 
dialysis patients during this period of time not only adds to the PM2.5 literature on susceptible 
population but also provides additional understanding the impact of low-level exposures. It is 
valuable to identify and study susceptible population for they could and often serve as the 
sentinel for the more general population with the fact that adverse effects could be more 





can enhance public health actions, medical advice, and influence individual behaviors to reduce 
overall health risk. Furthermore, the findings of this project would inform intervention 
development and policy migration at the era of low PM2.5 exposure. The third specific aim of this 
dissertation assessed the association between short-term PM2.5 exposure with some of the closely 
monitored biomarkers for dialysis patients. Access to these regularly measured markers on the 
individual level provides this unique opportunity to generate insights for pathogenic mechanisms 
of PM2.5.  
 Access to the entire USRDS population and one of the major U.S. dialysis provider’s 
clinical research database with a long follow-up periods provides the opportunity to generate 
representative results as the sample size is large, and furthermore, U.S. dialysis population is a 
more diverse population (in terms of race, social economic conditions, comorbidities status, and 
geographic regions). In addition, access to the rich and detailed information of these two datasets 
enables us to perform stratification analyses by different factors, which is meaningful in 
identifying further susceptible population to inform intervention focus. 
 In conclusion, answering the overarching question of how current U.S. ambient PM2.5 
exposure is impacting the dialysis population will provide evidence for policy mitigation and 
intervention development and ultimately promote health not only for dialysis patients but also for 






CHAPTER 3. METHODS AND MATERIALS 
 Overall, this dissertation utilized a retrospective cohort study setting. The geographic 
region of this study was the contiguous United States. This study was conducted among two 
separate cohorts of US maintenance hemodialysis patients identified from two databases: United 
States Renal Data System (USRDS) and DaVita clinical research database. In terms of study 
design, Specific Aim 1 and 2 utilized a cohort study framework, and Specific Aim 3 was a 
longitudinal study with repeated measurements. 
Study Population 
 For Specific Aim 1 and Aim 2, we included patients aged 18 years or older who initiated 
in-center maintenance hemodialysis treatment between Jan 1st 2011 and Dec 31st 2016 in the 
contiguous U.S. who had Medicare as primary payer. Participants were followed from the fourth 
month of dialysis initiation until first incident diagnosis of CVD, change of renal disease 
treatment modality (e.g. receiving kidney transplant), loss of Medicare coverage, death, or 
administrative end of study follow-up (Dec 31st 2016).  
 For Specific Aim 3, we constructed a retrospective cohort of US patients receiving 
incenter hemodialysis at one of the dialysis treatment organizations with available outcomes. 
First, hemodialysis patients in the US were identified from the United States Renal Data System 
(USRDS), a claim-based national registry of nearly all end-stage kidney disease (ESKD) patients 
in the states. We included patients who initiated in-center hemodialysis treatment at or after Jan 





dialysis initiation; and had Medicare as primary payer. Participants were followed from the 
fourth months of dialysis initiation until deaths, change of kidney disease treatment modality 
(e.g. receiving kidney transplant), loss of Medicare coverage, or the end of study follow-up (Dec 
31 2014). Then, the sub group of USRDS hemodialysis patients who were receiving dialysis 
treatments in one of the three major dialysis facilities in the US was identified by linkage of 
these two databases. HD patients who received dialysis treatment from the private dialysis 
provider and had records in the  database was included in the final cohort..  
United States Renal Data System (USRDS) 
 The United States Renal Data System (USRDS) database is the largest of its kind, a 
national registry, that include all patients in Medicare’s ESRD program. USRDS is funded by the 
National Institute of Diabetes and Digestive and Kidney Diseases. It has a nearly complete 
inclusion of all U.S. kidney disease patients who undergo maintenance in-center hemodialysis. 
The USRDS database includes patients’ demographic and diagnosis data, biochemical values, 
dialysis claims, and information on treatment history, hospitalization events, and 
physician/supplier services.(112) USRDS data originates from the Centers for Medicare & 
Medicaid Services (CMS), the Organ Procurement and transplantation Network, the Centers for 
Disease Control, the ESRD Networks, the U.S. Census, and select data from past and current 
USRDS Special Studies.(112) Some of the key data files from USRDS that has been utilized by 
this dissertation are described in the following section. 
 CMS ESRD Medical Evidence Report Form (CMS 2728) 
 CMS 2728 is used to register patients at the onset of ESRD and must be submitted by 
dialysis or transplant providers within 45 days of treatment initiation. It is used to ascertain 





of ESRD onset. Only one CMS 2728 is expected for each ESRD patients from the entire ESRD 
treatment period, unless changes of treatment modality. 
 CMS ESRD Death Notification Form (CMS 2746) 
 CMS 2746 is used to report the death of ESRD patients. It must be submitted by dialysis 
or transplant providers within 30 days of a patient’s death. This is the primary source of death 
information for CMS and the USRDS, documenting more than 99% of deaths. It contains 
information on the date, primary and secondary causes of death, reasons for discontinuation of 
renal replacement therapy, if applicable, and evidence of hospice care prior to death. 
 CMS ESRD Standard Analytical Files 
 The Standard Analytical Files contain data from final action claims submitted by 
Medicare beneficiaries, in which all adjustments have been resolved. It contains two parts: Part 
A Institutional Claims, and Part B Physician/Supplier. For this dissertation, Part A will be used 
heavily as it contains inpatients and outpatient claims. 
 CMS Annual Facility Survey (CMS 2744) 
 All Medicare-certified dialysis units and transplant centers are required to complete this 
form at the end of each calendar years. The Annual Facility Survey reports counts of patients 
being treated at the end of the year, new ESRD patients starting during the year, and patients 
who died during the year.  
DaVita Clinical Research Database 
 DaVita is a U.S. large dialysis provider, and it maintains a clinical research database that 
is linkable to USRDS for various studies. Each year, DaVita Inc. treats about one-third of the 
total U.S. ESRD patient population- about 188,000 patients receiving hemodialysis. DaVita 





rural, and suburban areas. DaVita Clinical Research (DCR) databases contains comprehensive 
patient-level data including repeated measured standard and dialysis specific laboratory 
measurements. This database captures detailed clinical, laboratory, and treatment data on patients 
who receive dialysis treatment at their dialysis units. The DCR data are collected with 
standardized clinical protocols from electronic record system.(113)  
Exposure Assessment 
 The primary exposure of interest for this dissertation is ambient PM2.5 concentrations. 
Both short- and long-term ambient PM2.5 exposures were considered. Aim 1 and 3 focused on the 
short-term PM2.5 exposure’s impact on mortality, CV events, and repeatedly measured 
biomarkers. In Aim 2, the long-term PM2.5 exposure’s health impact was examined.  
Short Term PM2.5 Exposure (Aim 1 and Aim 3) 
 For short term PM2.5 exposure, the ZIP code-level daily ambient PM2.5 concentration in 
the unit of g/m3 was retrieved for the same day of the day of death, CVD ED visits, CVD 
hospitalization, or the biomarkers were measured for each included dialysis patient based on the 
patient’s dialysis clinic address. The lagged-effect of the short-term exposure was assessed up to 
3 days before the events (deaths, CVD onset, or biomarkers measurement) took place, as most of 
the previous study assessed shot-term effect of PM2.5 exposure 0-3 day prior to the adverse 
health event. This short-term lag period were decided based on our previous analysis among HD 
patients. 
Long Term PM2.5 Exposure (Aim 2) 
 In addition to the acute effect associated with short-term exposure, studies have also 
suggested that exposure to PM over a longer period of time poses threats to health as well. 





effect associated with particulate matter exposure. Long-term PM2.5 exposure was defined as the 
annual-average (across 365-day prior to the outcome) of the daily PM2.5 concentrations. To 
assess the potential variation in effect estimates by different definition of long-term exposure 
used, we also performed sensitivity analysis with different definitions on long-term exposure (6-
month, and 2-year moving averages). Previous studies of the long-term PM2.5 effect have used 
the annual average as the long-term exposure measurement.(3) In addition, national and 
international regulators like US Environmental Protection Agency and World Health 
Organization have set long-term PM2.5 regulatory standards on the scale of annual-average. 
PM2.5 Exposure Data Source 
 ZIP code-level daily PM2.5 concentrations were estimated with a previously described 
prediction model.(114, 115). This set of PM2.5 concentration estimates have been validated and 
recently used to assess the lower-than-standard PM2.5’s impact on mortality among U.S. 
Medicare population.(5, 116) The detailed specification on how this set of exposure 
measurement were generated can be found elsewhere.(115, 117) In brief, an artificial neural 
network incorporated satellite-based measurements, simulation outputs from a chemical transport 
model, land-use terms, meteorological data, and other data to predict daily concentration of 
PM2.5 at un-monitored locations. The neural network model was also fitted with monitoring data 
from the EPA Air Quality System (AQS). Daily PM2.5 concentration (in the unit of g/m3) was 
then predicted for nationwide 1 km by 1 km grids. Gridded PM2.5 estimates were then converted 
to population-weighted ZIP-level estimates using 2010 Census tract population values. Cross-
validation was performed and indicated that predictions were of high quality.(116) With the fine 
resolution (1km by 1km, this is a sophisticated model of high spatial and temporal resolution 






 For Aim 1 and Aim 2, the outcomes of mortality and first onset of cardiovascular 
endpoints were obtained from the USRDS database, and for Aim 3, the closely monitored 
biomarkers together with standard examination measurement (blood pressures) were obtained 
from the DaVita clinical research database.  
Mortality 
 Specific Aim 1 and 2 assessed both all-cause and CVD-specific mortality. The date and, 
causes of each death for include patients during the study period will be obtained from CMS 
2746 from the USRDS database. The cause of death coded in the Death Notification Form was 
used to categorize death into all-cause and CVD-specific mortalities. Any death coded with 
primary cause of death as any of the listed CVD related conditions in Table 3-1 was considered 
to be CVD-related mortality. 
Table 3-1. Cause of death and ICD codes used to identify CV event. 
Event Codes 
CVD related mortality Primary Cause of Death* 
 23, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36 
CVD related emergency 
department visits and 
hospitalization 
ICD-9 ICD-10 
Hypertensive disease 402, 404 I11, I13 
Ischemic heart disease 410, 411, 412, 413, 414 I20, I21, I22, I23, I24, I25. 
Heart failure, cardiac arrest, 
and related 
398, 420, 421, 422, 423, 424, 
425, 426, 427, 428, 429 
I09, I30, I31, I32, I33, I34, 
I35, I36, I37, I38, I39, I40, 
I41, I42, I43, I44, I45, I46, 
I47, I48, I49, I50, I51. 
Cerebrovascular 
430, 431, 432, 433, 434, 435, 
436, 437, 438 
I60, I61, I62, I63, I64, I65, 
I66, I67, I68, I69, G45, G46. 
* The primary cause of death codes are based on the CMS 2746 form list of causes. 
CV Event 
 In observational studies, cardiovascular outcomes are often assessed as cardiovascular 





Specific Aim 1 and 2, we defined CV events as the first cardiovascular related emergency 
department (ED) visit, hospitalization, or mortality, which ever occurred first since the follow-up 
start. It is worth noting that, conventionally, “incident CVD event” or “CVD incidence” are 
studied only among participants determined to be free of CVD at baseline, and this analysis 
expands to all participants regardless of their baseline CVD status to understand HD patients’ 
overall CVD burden. International Classification of Disease, 9th and 10th Revision (ICD-9, ICD-
10) codes were used to identify cause-specific ED visit and inpatients cardiovascular events. In 
brief, any ED and hospitalization with a code indicating cerebrovascular, ischemic heart disease, 
hypertensive disease, heart failure, cardiac arrest, and related events were classified as CVD 
related ED and hospitalization events. The cause of death codes and International Classification 
of Disease codes used are summarized in Table 3-1. 
Biomarkers 
 For Aim 3, the repeatedly measured serum ferritin, albumin, serum hemoglobin, 
transferrin saturation (TSAT), and blood pressure were the outcomes of interest based on 
plausible biological mechanisms of PM2.5 exposure and their clinical importance for treatment 
effects and health condition monitoring. For this dissertation biomarkers related to inflammation 
were selected because previous studies have suggested that PM2.5 exposure causes adverse health 
outcomes through inflammation related pathways. Inflammation is common among maintenance 
dialysis patients, and the prevalence had been estimated to be as high as 40-60%.(118) 
Inflammation together with malnutrition are two predominant predictors for poor dialysis 
outcomes.(118, 119) Pre-dialysis blood pressures were also included as outcomes of interest, and 
previous literature has linked ambient PM2.5 exposure with blood-pressure changes in the general 





Research dataset for the individuals who met the inclusion criteria for Aim 1 and were linkable 
in DaVita. Table 3-2 is a summary on current understanding of each biomarkers and availability 
in DaVita. 
In addition to treating each biomarker as a continuous outcome separately, we also 
dichotomized those laboratory measurements into categories by clinically meaningful thresholds 
to further assess PM exposure’s impact on health. The cut-points used to dichotomized 
biomarker measurements were: high ferritin (2000 ng/mL), low albumin (< 3.5 g/dL), and low 
TSAT (<20%), and low hemoglobin (<10 g/dL). No cut-point for blood pressure were applied 
because the management goal of blood pressure among HD patients was not determined, and 
studies have associated adverse health outcomes with both decreased and elevated blood 
pressures among dialysis patients.(99, 120) Thus, for blood pressures, only the change in values 
was assessed. 
Table 3-2. Summary of Aim 3 outcomes of interest 
Lab Measures Cut-points 
Implication For 
ESRD patients Literature on PM2.5 
Transferrin Saturation 
(TSAT): measured as a 
percentage; serum iron 




Indicator for iron 
status. TSAT is a 
significant 
independent risk 
factor for adverse 
clinical outcome, 
which could be 




There is no published 
literature on TSAT 
level and particulate 
matter exposures. We 
selected it for its 
potency as an 
inflammatory marker. 
Serum Ferritin: blood cell 
protein that contains iron; 
measured as nano grams per 
milliliter of blood (ng/mL) 
>2000 





indicative of  
inflammation.(119) 
One cross-sectional 
study with 866 
hemodialysis patients 
demonstrated that 
serum ferritin level and 
number of days of high 






Elevated Ferritin = 
iron store + 
inflammation + 




Serum Hemoglobin: a type 
of oxygen-carrying protein; 
measured as gram per 
deciliter of blood (g/dL) 
<10 
Low value indicates 
anemia. 
Study suggests that 
serum hemoglobin 
is significantly 








Study has observed 
that with an inter-
quantile range (IOR, 
3.9 g/m3) increase in 
the one year moving 
average PM2.5 was 
positively associated 
decreases in average 
hemoglobin of 0.81 
g/dL among 4,121 
older Americans.(122) 
Serum Albumin: is a kind 
of water-soluble globular 
protein; measured as gram 
per deciliter of blood (g/dL) 
<3.5 
Albumin helps with 
fluid removal during 
a dialysis treatment. 
Albumin provides 
the body with the 
protein needed to 




albumin level had a 







There is no study 
assessing the 
association between 
serum albumin level 
and PM exposure. 
Serum albumin was 
selected for its potency 
as an inflammatory 
marker. 
Pre-dialysis Blood 
Pressures: both systolic 
blood pressure (SBP) and 













Several studies have 
assessed the 
association between 
PM2.5 exposure and 
blood pressure. But the 
results are mixed.(1) 
Some suggest elevated 
exposure is associated 









 For this dissertation, the potential confounders were adjusted for by including relevant 
covariates in regression models. The primary exposure of interest for this dissertation was the 
ambient PM2.5 exposure, the outcomes were mortality, cardiovascular conditions, and regularly 
measured biomarkers. Thus, factors impacting both the ambient PM2.5 levels and the outcomes 
were adjusted as the potential confounders to ensure internal validity of study results, and they 
were identified using directed acyclic graph based on precious literature. For Aim 1 and Aim 2, 
all potential confounders listed were adjusted in the final model together with other potential 
strong predictors of outcomes. For Aim 3, selected potential covariates were adjusted in the final 
model. The potential effect measure modifiers was assessed by stratification analysis. 
Assessment of effect modifiers helps further identifying susceptible group among this already 
vulnerable population. 
Potential Confounders 
 Geographic region: ambient PM2.5 distribution varies across different geographic 
regions. The outcome of mortality and cardiovascular outcomes can also distribute differently 
across various geographic regions, which could be explained by differences in health care or 
health seeking behaviors.(127) Thus, for Aim 1, Aim 2, we controlled for geographic regions by 
including a dummy term for four regions (Northeast, Midwest, South, and West) of contiguous 
United States in the model assessing. By including this term in the model, some of the 
unmeasured individual level confounders like income and health care service utilization were 





Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania. The 
Midwest consists of Ohio, Michigan, Indiana, Wisconsin, Illinois, Minnesota, Iowa, Missouri, 
North Dakota, South Dakota, Nebraska, and Kansas. The South includes Delaware, Maryland, 
Virginia, West Virginia, Kentucky, North Carolina, South Carolina, Tennessee, Georgia, Florida, 
Alabama, Mississippi, Arkansas, Louisiana, Texas, and Oklahoma. The West includes Montana, 
Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, California, Oregon, and 
Washington. In theory, finer geographic region could be used to control for potential spatial 
confounding. However, taking available computing capacity and the large sample size of this 
analysis into account, we decided to use this larger unit.  
 Ambient Temperature: daily ambient PM2.5 level is affected by meteorological factors 
like ambient temperature. (128, 129) Temperature is suggested to be associated with mortality 
and other health outcomes in general population.(130) Thus, we controlled for temperature in the 
final analysis as linear ZIP code-level daily temperature. Temperature data was obtained from 
National Oceanic and Atmospheric Administration (NOAA) database.(131, 132) In detail, daily 
temperature from weather station measurements were interpolated to census tract centroids and 
then averaged over tracts to ZIP codes. 
 Relative Humidity: daily ambient PM2.5 level is also affected by relative humidity, 
another meteorological factor.(133) Relative humidity has also been linked with health outcomes 
among general populations.(134) Thus, we controlled for relative humidity in the final analysis 
as linear ZIP code-level daily relative humidity. Relative humidity data was also obtained from 
NOAA database.(131, 132) In detail, daily relative humidity from weather station measurements 





 Seasonality: seasonality is also an established determinant of ambient PM2.5 level.(1) 
Seasonal ambient PM2.5 concentration fluctuations have been observed across different 
geographic regions.(135) In our previous analysis, we observed a seasonal trend in U.S. 
hemodialysis mortality counts. In our analyses, season was assigned to each outcome or 
biomarker measurements based on the calendar dates. Dates between December to February, 
March to May, June to August, and September to November were assigned as winter, spring, 
summer and autumn, respectively. 
 Socioeconomic Status: population with lower social economic status (SES) is suggested 
to be more likely to be residing in areas with elevated level of ambient PM2.5 and also more 
likely to experience PM2.5 exposure associated health outcomes. We used the CMS 2728 
information on the Employment status at dialysis initiation as surrogate for dialysis patient’s 
social economic status. Employments status is not usually considered the most representative or 
typical surrogates for SES, but this is the most relevant variable on SES we had access to in 
USRDS. 
 Race: previous studies on PM2.5-related health impact suggests that minority race groups 
are susceptible for ambient PM2.5 exposure.(1) The recent study by Di et al. observed that risk of 
death associated with PM2.5 exposure among U.S. Medicare population was significantly higher 
among Blacks compared to other race groups or the general population.(116) In addition, studies 
also suggest that racial minority groups tend to reside in areas with elevated ambient PM2.5 
exposures. In this analysis, race was controlled as a social factor in the model. Race for each 







Potential Effect Measure Modifiers 
 Age: age is both a potential confounder and a potential effect modifier for PM2.5 
exposure’s health impact among dialysis patients. As mentioned previously, the older dialysis 
patients have worse clinical outcomes and lower life expectancy compared to those with younger 
age. Studies also suggest the age could modify the effect of PM2.5 exposure.(1) Older individuals 
tend to have an elevated risk of experiencing PM2.5-related adverse health outcomes.(3) Thus, for 
this project, age (in the unit of year) was adjusted in the model for its potential confounding 
effect and was also assessed as one of the potential effect modifiers. Age at dialysis initiation age 
from CMS 2728 was obtained from USRDS data files.  
 Gender: studies suggest that gender could modify the effect of PM2.5 exposure. Di et al. 
observed the mortality risks associated with PM2.5 exposure is different by gender among U.S. 
Medicare population.(116) Thus, we performed subgroup analysis by gender. The information on 
gender was obtained from CMS 2728 form of USRDS data files.  
 Dialysis Initiation Comorbidity Status: studies demonstrated that populations with 
different pre-existing morbidities could experience different magnitude of PM2.5 related 
effects.(1, 3) Therefore, we performed sub-group analysis by comorbidity status at dialysis 
initiation. The study population was classified into subgroups: with and without diabetes, with 
and without cardiovascular diseases, and with and without respiratory conditions. This 
classification was based on the comorbidities status recorded in CMS 2728 form collected at the 
start of dialysis treatment. The patients who reported to have any of the following conditions: 
atherosclerotic heart disease (ASHD), cardiac arrest, congestive heart failure (CHF), 
cerebrovascular disease, cardiac dysrhythmia, ischemic heart disease (IHD), myocardial 





classified to have CVD at baseline. The patients who reported to have diabetes (primary or 
contributing), who were diabetic and currently on insulin, on oral medications, or without 
medications, or with retinopathy diabetes were classified to have diabetes at baseline. The 
patients who reported to have chronic obstructive pulmonary disease were classified to have 
COPD at baseline. 
Data Linkage 
 The linkage between ZIP code-level exposure, weather, and outcome data was based on 
the provided dialysis clinic address obtained from USRDS claims. For each participant-day 
under follow-up, a daily record of location, at the ZIP code-level, was assigned based on the ZIP 
code of the dialysis clinic visited during that period. Patients typically visited dialysis clinics 
every 2 to 3 days. For a date between claim reporting periods (with no information on clinic 
visits), the ZIP code of the last clinic visited was assigned. Previous studies have shown that 
patients in the USRDS cohort have a median travel distance of 5.7 miles to their dialysis 
clinic.(136, 137) Thus, ZIP code assignment based on dialysis clinic location should be a 
relatively accurate surrogate for hemodialysis patients’ geographic location of residence during 
study follow-up.  
 The linkage between USRDS and DaVita for Aim 3 was performed by a data manager 
who knows both datasets well. The linkage was based on the USRDS ID to identify the 
individual dialysis patients who receive dialysis treatment at DaVita dialysis clinics and with 
repeatedly measured biomarker measurements available during the study period. 
Statistical Analysis  
 Standard descriptive statistics were conducted to describe the characteristics of study 





chronic hemodialysis initiation (mean), time on chronic dialysis treatment (mean), gender 
(%male), race (% White, Black, and other), body mass index (mean and standard deviation), 
cause of end-stage renal disease (% hypertension, diabetes, glomerulonephritis, and other), 
access type at dialysis initiation (% AVF=arteriovenous fistula, CATH=catheter, Graft and 
other), comorbidities status (diabetes, congestive heart failure, chronic obstructive pulmonary 
disease, and cancer) at dialysis initiation. These baseline characteristics were obtained from CMS 
2728 form from the USRDS database, and all the information recorded on this form was 
measured/reported at the start of dialysis initiation. 
Aim 1 
 Aim 1 assessed the association between short-term ambient PM2.5 exposure with CV 
event, all-cause mortality, and CVD-specific mortality. Both the same day and the lagged effect 
up to 3 days prior were assessed. We utilized discrete time hazards models to assess the 
association between ZIP code-level short-term PM2.5 exposure with mortality and CVD 
events.(138) Discrete time hazards models have been widely used in occupational and 
environmental cohort studies. This approach is similar to a Poisson regression model applied to a 
person-period data structure, which allows controlling for individual level factors.(138) Hazard 
ratios (HRs) per 10-µg/m3 increase in PM2.5, together with corresponding 95% confidence 
intervals (95% CIs) were estimated. We incorporated time since initiation of dialysis in the 
model as the analysis time scale to control for the potential temporal variation in baseline risk of 
the outcome of interest by this factor, which has been suggested to be an important predictor of 
mortality among dialysis patients in prior studies.(139, 140) Time-varying confounders 
including: daily temperature, daily relative humidity, day of the week (DOW), and season (warm 





and season were incorporated to account for short- and long-term temporal variability of the 
outcomes.(141, 142) Time-invariant confounders included age at dialysis initiation, race, 
baseline employment status, and geographic region (Northeast, Midwest, South, and West). 
Baseline employment status was incorporated as a surrogate for socio-economic status.  
Short-term PM2.5 exposure effects were assessed for the same day, lag days, and moving 
averages across different lag periods to assess the persistent effect of PM2.5 exposure on CVD 
risk across multiple days. The same day (lag day 0) effects were assessed in a model for that 
same day PM2.5 and its association with the outcome. The lagged effects of prior days’ exposures 
were assessed in a model that associated lag day 0, 1, 2, and 3 exposures with the outcome in the 
same model. The average lagged effects of prior exposure days were assessed in a model that 
associated the average of daily PM2.5 across lag periods 0-1, 0-2, or 0-3 days prior.  
Potential effect measure modification by baseline comorbidity status, race, sex, and age 
at dialysis initiation were assessed. The comorbidities assessed were diabetes, CVD, and chronic 
obstructive pulmonary disease (COPD) reported at the start of maintenance hemodialysis on 
CMS 2728 form. Likelihood ratio tests for homogeneity were performed by comparing models 
with and without an interaction term between the potential modifier and PM term. A small Chi-
square test of likelihood ratios test p-value (less than 0.05) suggested the rejection of effect 
homogeneity hypothesis, which indicates PM effects are not similar across different levels of 
potential modifiers. 
Aim 2 
We utilized discrete time hazards models to assess the association between ZIP code-
level long-term PM2.5 exposure with mortality and CVD events as well.(138) Hazard ratios 





(95% CIs) were estimated. We incorporated time since the initiation of dialysis as the analysis 
time scale to control for the potential temporal effect variation by this factor, which has been 
suggested to be a predictor of mortality and comorbidities among dialysis patients.(139, 140) 
Daily temperature, daily relative humidity, DOW (day of the week), season (spring, summer, 
fall, and winter) were included to control for potential time varying confounding. Specifically, 
DOW and season were incorporated to account for short- and long-term temporal variability of 
the outcomes.(141, 142) Time-invariant confounders included age at dialysis initiation, race, 
baseline employment status, and geographic region (Northeast, Midwest, South, and West). 
Baseline employment status was incorporated as a surrogate for socio-economic status (SES) as 
classical SES variables like income or education level information were not available.  
Potential effect measure modifications by baseline comorbidity statuses, race, sex, and 
dialysis initiating age were assessed. The comorbidities assessed were diabetes, CVD, and 
chronic obstructive pulmonary disease reported at the start of maintenance hemodialysis on the 
CMS 2728 form. Likelihood ratio tests for homogeneity were performed by comparing models 
with and without an interaction term between the potential modifier and PM term. A small Chi-
square test of likelihood ratios test p-value (less than 0.05) suggested the rejection of effect 
homogeneity hypothesis, indicating PM effects are not equivalent across different levels of 
potential modifiers. 
Aim 3 
 We used a generalized mixed model with random intercept for individual patient to 
estimate the short-term effect of PM2.5 exposure on individual biomarkers’ absolute levels. We 
used generalized estimating equation (GEE) model to assess PM2.5 short-term effect on binary 





model, the absolute change (increase or decrease) of biomarker values associated with every 10 
µg/m3 increase in PM2.5, together with corresponding 95% confidence intervals (95% CIs), were 
estimated. With the GEE model, the relative risk (RR) associated with every 10 µg/m3 increase 
in PM2.5 were estimated with corresponding 95% confidence intervals (95% CIs). To control for 
potential confounding effect, we controlled for both time-varying and -invariant factors. Time-
varying factors included daily temperature, relative humidity, and time since study beginning. 
Time-invariant factors included patient’s age at dialysis initiation and race. For ferritin, TSAT, 
and hemoglobin analysis, we considered the treatment effect of iron supplements (impacting 
ferritin and TSAT level) and erythropoietin (impacting hemoglobin level) as primary factors that 
influence the markers levels due to their considerable applications among hemodialysis patients. 
To control for those treatment effects that potentially mask or dilute the PM2.5 effect we are 
interested in, we applied a 90-day washout period to excluding any ferritin, TSAT measurement 
occurred within 90-day from the last intravenous (IV) iron treatment and excluding any 
hemoglobin measurement occurred within 90-day from the last Epogen treatment.  
To assess the potential lagged-effect of short-term PM2.5 exposure, we also performed 
analyses for lagged effect up to 3 days prior of the day when each outcome were measured. The 
lagged effects of prior days’ exposures were assessed in a model that associated lag day 0, 1, 2, 
and 3 exposures with the outcome in the same model adjusting for race, age at dialysis initiation, 











To assess for the potential variation of effect by different definitions (time windows) of 
long-term PM2.5 exposure, we assessed the effect of 6-month- and 2-year- average of daily PM2.5 
in addition to the annual average.  
Aim 3 
To assure that the 90-day washout period approach was a reliable way to control for 
potential treatment effect by iron supplements and anemia treatment, we utilized two additional 
methods to exclude or adjust for the treatments. We restricted our analysis to measurements that 
occurred before the patients received their first-ever treatment (IV iron for ferritin and TSAT; 
Epogen for hemoglobin). In addition, we controlled for the 90-day prior treatment history in the 







CHAPTER 4. SHORT-TERM PM2.5 EXPOSURE AND DIALYSIS PATIENTS 
INTRODUCTION 
Short-term exposure to PM2.5 (particles with a mass median aerodynamic diameter of less 
than 2.5 µm) is an established cause of cardiovascular disease and mortality(3), and is a criteria 
air pollutant regulated by US National Ambient Air Quality Standards (NAAQS). When inhaled, 
PM2.5 particles can travel deep into the lung and even enter the circulatory system.(143) PM2.5 
particles can trigger inflammation (both systemic and local) and oxidative stress, accelerate 
atherosclerosis, and alter cardiac autonomic function which can eventually lead to cardiovascular 
diseases and ultimately deaths.(23-26, 28, 71)  
Previous studies have established ambient PM2.5 as a cause of cardiovascular disease and 
mortality in the general population; however, less is known about the risks associated with PM2.5 
exposure among subgroups of the population that may be particularly susceptible to PM2.5 -
associated health effects.(3, 8) One such group are patients with kidney failure requiring dialysis. 
These individuals have a higher cardiovascular disease (CVD) risk than the population, and US 
dialysis patients have an annual all-cause mortality risk of 16%.(6, 8, 81, 83, 144) Quantifying 
the mortality risk from air pollution is a critical step in identifying modifiable adverse health 
outcome risk factors in this population. Yet, to our knowledge, there has been no prior 






Therefore, we assessed the association of short-term ambient PM2.5 exposure with new 
CVD events, and with mortality among patients receiving maintenance in-center hemodialysis 
(HD) in the contiguous United States, considering lagged effects of exposure (up to 3 days after 
exposure) and potential effect measure modifications by age, sex, race, and baseline 
comorbidities. 
METHODS 
Study Setting and Study Population 
We identified a retrospective cohort of maintenance hemodialysis patients from the 
United States Renal Data System (USRDS), a claim-based national registry of renal disease 
patients. USRDS includes nearly all dialysis patients in the United States with individual level 
data on patients’ demographics, hospitalizations, and provider information.(112) Baseline 
demographic characteristics, dialysis treatment, and comorbidity status were extracted. We 
included patients aged 18 years or older who initiated in-center maintenance hemodialysis 
treatment between Jan 1st 2011 and Dec 31st 2016 in the contiguous U.S. who had Medicare as 
primary payer. Participants were followed from the fourth month of dialysis initiation until first 
incident diagnosis of CVD, change of renal disease treatment modality (e.g. receiving kidney 
transplant), loss of Medicare coverage, death, or administrative end of study follow-up (Dec 31st 
2016).  
Exposure Assessment and Weather Data 
For each participant-day under follow-up, a daily record of location, at the ZIP code-
level, was assigned based on the ZIP code of the dialysis clinic visited during that period. 
Patients typically visited dialysis clinics every 2 to 3 days. For a date between claim reporting 





(1.3% of the person-days in the analysis had a ZIP code that was different from the previous 
person-day of the same individual). Previous studies have shown that patients in the USRDS 
cohort have a median travel distance of 5.7 miles to their dialysis clinic.(136, 137) Thus, ZIP 
code assignment based on dialysis clinic location should be a relatively accurate surrogate for 
hemodialysis patients’ geographic location of residence during study follow-up. 
ZIP code-level daily PM2.5 concentrations were estimated with a previously described prediction 
model.(114, 115) In brief, this model estimates daily average PM2.5 on a 1*1 km grid for the 
entire contiguous U.S. by incorporating multiple inputs like chemical transport model 
simulations, satellite aerosol optical depth measurements, meteorology, and land use. Gridded 
PM2.5 estimates were then converted to population-weighted ZIP-level estimates using 2010 
Census tract population values. Daily temperature and relative humidity data were estimated 
based on records from the U.S. National Oceanic and Atmospheric Administration 
(NOAA).(131, 132)  In detail, daily temperature and relative humidity from weather station 
measurements were interpolated to census tract centroids and then averaged over tracts to ZIP 
codes. A patient’s daily record of location was linked to an estimate of the daily concentration of 
PM2.5 at that location, as well as an estimate of the temperature and relative humidity for that 
date and ZIP code.   
Outcome Assessment 
Follow-up to ascertain CV events, CVD-related deaths, and vital status through 
December 31, 2016 was based on USRDS records.(145)  The outcomes of interest were all-cause 
mortality, CVD-specific mortality, and CV event. The primary cause of death recorded in ESRD 
Death Notification Form (CMS 2746) was used to classify mortality into all-cause and CVD-





department (ED) visit, hospitalization, or mortality, which ever occurred first since the follow-up 
start. It is worth noting that, conventionally, “incident CVD event” or “CVD incidence” are only 
studied among participants determined to be free of CVD at baseline only, but this analysis 
expands to all included patients regardless of their baseline CVD status to understand HD 
patients’ CVD burden. International Classification of Disease, 9th and 10th Revision (ICD-9, 
ICD-10) codes were used to identify cause-specific ED visit and inpatients cardiovascular 
events. In brief, any ED and hospitalization with a code indicating cerebrovascular, ischemic 
heart disease, hypertensive disease, heart failure, cardiac arrest, and related events were 
classified as CVD related ED and hospitalization events. The cause of death codes and 
International Classification of Disease codes used are summarized in Table 4-2.  
Statistical Analysis 
We utilized discrete time hazards models to assess the association between ZIP code-
level short-term PM2.5 exposure with mortality and CVD events.(138) Discrete time hazards 
models have been widely used in occupational and environmental cohort studies. This approach 
is similar to a Poisson regression model applied to a person-period data structure, which allows 
controlling for individual level factors.(138) The equation for the fully-adjusted model is 
presented in Equation 1, where Y is the individual specific response at time t (e.g. 0 if no event, 
1 event….) and i, t, and k  index individual, time (day), and number of lag days respectively. We 
used a generalized linear model E(Yit| covariates) = g^{-1}(𝜂𝑖𝑡) with a complementary log-log 





𝑙𝑜𝑔 (−log (1 − E(Y𝑖𝑡| covariates)) = 𝜂𝑖𝑡
=  𝑀𝑜𝑛𝑡ℎ𝑆𝑖𝑛𝑐𝑒𝐷𝑖𝑎𝑙𝑦𝑠𝑖𝑠(𝑓𝑎𝑐𝑡𝑜𝑟)𝑚(𝑖𝑡) +  ∑𝑘=0
𝐾 𝛽1𝑘𝑃𝑀2.5𝑖𝑡𝑘
+ 𝛽2𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒𝑖𝑡 + 𝛽3𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝐻𝑢𝑚𝑖𝑑𝑖𝑡𝑦𝑖𝑡 + 𝛽4𝐷𝑂𝑊(𝑓𝑎𝑐𝑡𝑜𝑟)𝑖𝑡
+ 𝛽5𝑆𝑒𝑎𝑠𝑜𝑛(𝑓𝑎𝑐𝑡𝑜𝑟)𝑖𝑡 + 𝛽6𝐴𝑔𝑒(𝑑𝑖𝑎𝑙𝑦𝑠𝑖𝑠 𝑖𝑛𝑖𝑡𝑖𝑎𝑡𝑖𝑜𝑛)𝑖 + 𝛽7𝑅𝑎𝑐𝑒𝑖
+ 𝛽8𝐸𝑚𝑝𝑙𝑜𝑦𝑚𝑒𝑛𝑡𝑆𝑡𝑎𝑡𝑢𝑠𝑖 + 𝛽9𝑅𝑒𝑔𝑖𝑜𝑛𝑖 
Equation 1 
Variables DOW, Season, Race, Region and Employment status were categorical thus the 
coefficients represent vectors rather than scalars. Hazard ratios (HRs) per 10-µg/m3 increase in 
PM2.5, together with corresponding 95% confidence intervals (95% CIs) were estimated. We 
incorporated time since initiation of dialysis in the model as the analysis time scale to control for 
the potential temporal variation in baseline risk of the outcome of interest by this factor, which 
has been suggested to be an important predictor of mortality among dialysis patients in prior 
studies.(139, 140) Time-varying confounders including: daily temperature, daily relative 
humidity, day of the week (DOW), and season (warm vs. cold) were controlled for to adjust for 
potential time varying confounding. Specifically, DOW and season were incorporated to account 
for short- and long-term temporal variability of the outcomes.(141, 142) Time-invariant 
confounders included age at dialysis initiation, race, baseline employment status, and geographic 
region (Northeast, Midwest, South, and West). Baseline employment status (employed, 
unemployed, retired, other) was incorporated as a surrogate for socio-economic status (SES).  
Short-term PM2.5 exposure effects were assessed for the same day, lag days, and moving 
averages across different lag periods to assess the persistent effect of PM2.5 exposure across 
multiple days. The same day (lag day 0) effects were assessed in a model for that same day PM2.5 





in a model that associated lag day 0, 1, 2, and 3 exposures with the outcome in the same model. 
The average lagged effects of prior exposure days were assessed in a model that associated the 
average of daily PM2.5 across lag periods 0-1, 0-2, or 0-3 days prior. For example, the moving 
average of lag period 0-1 was calculated by averaging the exposure levels of the day of the event 
and the day preceding the event, which is later incorporated in the model as the sole exposure 
variable. Among different models assessing short-term lagged effect, the model with the lower 
Akaike information criterion (AIC) value was considered to be the better model depicting the 
short-term effects. 
Potential effect measure modification by baseline comorbidity status, race, sex, and age 
at dialysis initiation were assessed. The comorbidities assessed were diabetes, CVD, and chronic 
obstructive pulmonary disease (COPD) reported at the start of maintenance hemodialysis on 
CMS 2728 form. Specifically, the patients who reported to have any of the following conditions: 
atherosclerotic heart disease (ASHD), cardiac arrest, congestive heart failure (CHF), 
cerebrovascular disease, cardiac dysrhythmia, ischemic heart disease (IHD), myocardial 
infarction (MI), pericarditis, peripheral vascular disease, and other cardiac disease, were 
classified to have CVD at baseline. The patients who reported to have diabetes (primary or 
contributing), who were diabetic and currently on insulin, on oral medications, or without 
medications, or with diabetic retinopathy were classified to have diabetes at baseline. The 
patients who reported to have chronic obstructive pulmonary disease were classified to have 
COPD at baseline. 
Likelihood ratio tests for homogeneity were performed by comparing models with and 
without an interaction term between the potential modifier and PM term. A small Chi-square test 





hypothesis, which indicates PM effects are not similar across different levels of potential 
modifiers. 
The data management and statistical analysis were performed with SAS software, 
Version 9.4 (SAS Institute Inc., Cary, NC, USA). Plots were generated with R Project for 
Statistical Computing Version 3.5.0 (R Foundation for Statistical Computing, Vianna, Austria). 
The study protocol was reviewed and exempted by the Institutional Review Board of the 
University of North Carolina on Nov 16, 2020 (Study #:20-1469). 
RESULTS 
The final cohort included a total of 314,079 hemodialysis patients with 193,121,928 
person-days of follow-up in the mortality analysis and 94,385,773 person-days in  the CVD 
event analysis. Between 2011 and 2016, there were 82,567 deaths, 35,857 (43.4%) of which 
were CVD-related mortalities, and 208,113 patients experienced at least one CVD event.  
Table 4-1 displays the study population characteristics. At the initiation of hemodialysis, 
more than half of the participants were older than 65 years of age. The average vintage period , 
which is the time between dialysis initiation and the end of follow-up, was 1.9 (SD=1.4) years. 
Approximately 44% of the study participants were female, and 65% were white. At hemodialysis 
initiation, more than half of the cohort was reported to have diabetes, about 60% was reported to 
have CVD, and 10% was reported to have COPD. Patients who died during the study period 
were likely to be older at dialysis initiation compared to the overall study population or the 
cohort who experienced at least one CVD event. 
The distribution of ZIP code-level PM2.5 concentration is summarized in Table 4-3. For 
the mortality analysis, the average daily ZIP code-level PM2.5 was around 8.5 (±4.8) µg/m3 with 





distribution was similar to that of the mortality analysis with a mean of 8.6 (±4.9) µg/m3 and IQR 
of 5.3 µg/m3.  
All-Cause Mortality 
Exposure to short-term daily ambient PM2.5 was associated with an increased hazard of 
all-cause mortality (Figure 4-1, Table 4-4). Both immediate (same day) and lagged short-term 
PM2.5 effects were observed. The HR associated with a 10-µg/m3 increase in same day, lag-day 
1, lag-day 2, and lag-day 3 PM2.5 were 1.01 (95% CI: 0.99, 1.03), 1.03 (95% CI: 1.01, 1.06), 1.00 
(95% CI: 0.97, 1.02), and 1.00 (95% CI: 0.98, 1.02), respectively (Figure 4-1, Table 4-4). The 
short-term PM effects were most prominent for the same day and lag-day 1 exposure. The HR 
associated with a 10-µg/m3 of the average daily PM2.5 across same-day and lag-day 1 was 1.04 
(95% CI: 1.03, 1.06) (Figure 4-1). The HRs associated with average daily PM2.5 across same-day 
and lag-day 2, up to lag-day 3 were similar to the HR of average daily PM2.5 across same-day 
and lag-day 1 (Table 4-4). 
Patients who started dialysis in the oldest age group (≥75 years), were of white race, and 
did not have diabetes at dialysis initiation experienced relatively higher PM effects on all-cause 
mortality compared to other groups by these potential modifiers (Figure 4-2). The highest HR of 
1.07 (95% CI: 1.05, 1.10) associated with every10-µg/m3 increase in average daily PM2.5 across 
lag-day 0 and 1 was observed among patients who initiated dialysis at the age of 75-year or older 
(Figure 4-2). The likelihood ratio test for homogeneity also suggested PM mortality effects are 
not homogeneous across levels of dialysis initiating age, race, and baseline diabetes status with 







Exposure to short-term daily ambient PM2.5 was associated with an elevated hazard of 
CVD-specific mortality (Figure 4-1, Table 4-4). The HR associated with a 10-µg/m3 increase in 
same day, lag-day 1, lag-day 2, and lag-day 3 PM2.5 were 1.02 (95% CI: 0.99, 1.05), 1.03 (95% 
CI, 0.99: 1.07), 0.99 (95% CI: 0.96, 1.03), and 1.01 (95% CI: 0.98, 1.04), respectively (Table 4-
4). The short-term PM effects were most prominent for the same day and lag-day 1 exposure for 
CVD-specific mortality. The HR associated with a 10-µg/m3 of the average daily PM2.5 across 
same-day and lag-day 1 was 1.05 (95% CI: 1.03, 1.08) (Figure 4-1). The HRs associated with 
average daily PM2.5 across same-day up to lag-day 3 which were similar to the HR of average 
daily PM2.5 across same-day and lag-day 1 (Table 4-4). 
Similar to the effect measure modification effect observed for all-cause mortality, HD 
patients who initiated dialysis in the oldest age group (≥75 years), were of white race, and did 
not have diabetes at dialysis initiation experienced relatively higher PM effects on CVD-cause 
mortality compared to other groups by these potential modifiers (Figure 4-3). The highest HR of 
1.10 (95% CI: 1.06, 1.14) associated with every10-µg/m3 increase in average daily PM2.5 across 
lag-day 0 and 1 was observed among hemodialysis patients who initiated dialysis at the age of 
75-year or older (Figure 4-2). The likelihood ratio test for homogeneity also suggested the PM 
effect are not homogeneous across levels of dialysis initiating age, race, and baseline diabetes 
status for CVD-specific mortality (Table 4-5). 
CV Events 
Exposure to short-term daily ambient PM2.5 was associated with a higher hazard of CV 
events (Figure 4-1, Table 4-4). The HR associated with a 10-µg/m3 increase in same day, lag-day 





(95% CI: 0.98, 1.01), and 1.00 (95% CI: 0.99, 1.01), respectively (Table 4-4). The short-term 
PM effects were most prominent for the same day and lag-day 1 exposure for cardiovascular 
related events. Effects at lag-day 2 and lag-day 3 daily PM2.5 were not observed (Table 4-4). The 
HR associated with a 10-µg/m3 of the average daily PM2.5 across same-day and lag-day 1 was 
1.03 (95% CI: 1.03, 1.04) (Figure 4-1, Table 4-4). The HRs associated with long lag periods (lag 
0-2 or lag 0-3) average daily PM2.5 was very similar to the HR of the lag 0-1 average PM2.5 
(Table 4-4).  
For CV events, none of the factors assessed significantly modified the short-term PM 
effect. Slightly higher hazards were observed among hemodialysis patients who had COPD at 
baseline and who were males with overlapping confidence interval ranges (Figure 4-4). The 
likelihood ratio test of homogeneity also indicates the PM effects were similar across different 
levels of dialysis initiating age, race, and baseline diabetes status for CV events with greater than 
0.05 p-values (Table 4-5). 
DISCUSSION 
We estimated associations between short-term PM2.5, all-cause mortality, CVD-specific 
mortality, and CV event among US hemodialysis patients during the period 2011-2016.  Short-
term PM2.5 exposure was associated with elevated hazards for all-cause mortality, CVD-specific 
mortality, and CV event among the study population. Each 10 µg/m3 increase in short-term PM2.5 
was associated with a 4%, 5%, and 3% increase in the hazard of all-cause mortality, CVD-
specific mortality, and CV events, respectively. We also observed relatively higher PM2.5 
hazards on all-cause mortality and CVD-specific mortality among hemodialysis patients who 
initiated dialysis at an older age, who were white, and who did not report having diabetes 





The effects of PM2.5 exposure among US hemodialysis patients have not been extensively 
evaluated. To our knowledge, this is the first study to examine short-term ambient PM2.5 
exposure effects among US hemodialysis patients. We previously observed an elevated mortality 
risk associated with wildfire generated PM2.5 exposure among maintenance hemodialysis 
patients.(102) In addition to mortality, we also observed an elevated CV event hazard associated 
with short-term PM2.5 exposure, which is consistent with a study among hemodialysis patients on 
the association between hospital admission and county-level short-term PM2.5 for cardiovascular 
causes for the same-day PM2.5 exposure.(103) Wyatt et al. reported a 0.9% (95% CI, 0.4, 1.8%) 
increase in hospital admission risk for cardiovascular causes for the same-day PM2.5 
exposure.(103) Recently, a study demonstrated an elevated risk of all-cause mortality associated 
with long-term (annual average) PM2.5 among older (over 65-year old) US hemodialysis and 
peritoneal dialysis patients.(11) Their study reported that for very 10 µg/m3 increase in annual 
average PM2.5 exposure below 12 µg/m3, there is a 1-5% increase in the HR of all-cause 
mortality, a similar range to our findings.(11) However, it was unexpected that the association 
between PM2.5 and CV event was slightly lower than between PM2.5 and CVD-specific mortality 
(3% vs. 5% increase in HR per 10 µg/m3 increase in PM2.5, albeit with overlapping confidence 
intervals) because it is logical that a person would develop one or more CV condition(s) before 
he or she can die from it. However, this could be due to the different diagnosis coding regimes 
used to define CVD-specific mortality vs. CV events. CVD mortalities were defined using CMS 
2746 codes, which is not ICD-9 or -10 codes used for CV events, and future studies should 
identify and use additional data sources on cause of death. Another possible explanation is that 
PM2.5 exposure could impact the CVD case fatality rate, which could be assessed in future 





and to further understand PM’s impact on cardiovascular health among this population. In 
addition, evidence is emerging that elevated levels of fine particulate matter may contribute to 
incident chronic kidney disease, and its progression to severe kidney function impairment that 
requires maintenance dialysis treatment.(146-148) Together with previously published studies, 
our findings support the conclusion that there is an elevated health hazard associated with 
particulate matter exposure among dialysis patients. Furthermore, the daily ZIP code-level PM2.5 
for the majority (Q3 of 10.6 µg/m3) of the included person-days in this analysis were below the 
current NAAQS regulatory standard of 35 µg/m3 (24-hour, 98th percentile). On average, PM2.5 
has been decreasing nationally in the US over the last decade.(149) However, the PM 
concentration in many highly-populated urban areas still exceed the NAAQS, and extreme 
events like wildfires also lead to short-term high-level exposures. Our findings of elevated 
hazards of mortality and CVD conditions suggest that reduction of individual-level exposure 
may be beneficial to at risk individuals such as dialysis patients, a group that continues to 
increase in size in the US. 
Our findings suggest that there is larger magnitude of association between PM2.5 and 
mortality (both all-cause and CVD-specific) among patients who initiated dialysis treatment at an 
older age compared to younger dialysis initiators (Figure 4-2, Figure 4-3). The highest PM2.5 
effects were observed among the oldest age group (75 or older at the initiation of dialysis). This 
effect modification observed could be explained by the higher prevalence of pre-existing 
conditions and higher mortality risk among this age group.(150, 151) To our knowledge, only 
one previous study has assessed the effect of PM exposure on outcomes by age groups among 
dialysis patients. Feng et al. observed a higher long-term PM2.5 exposure effect on all-cause 





those who initiated dialysis 65-74 years.(11) Even though Feng et al.’s study population was 
different from our analysis, and they included peritoneal dialysis patients, our findings agrees 
that kidney disease patients who initiated dialysis at the age of 75 or older were likely to be 
particularly susceptible to PM2.5 exposure for all-cause mortality. This finding adds to the 
evidence that older hemodialysis patients should be targeted for exposure mitigation to reduce 
the overall public health burden in association with PM exposure 
In addition to older dialysis initiators, the results also suggest a larger magnitude of 
association between PM2.5 and mortality among white patients than non-white patients. This 
difference association by race could be partially explained by differences in age distribution of 
dialysis patients by race (Table 4-6). About 29.5% (15.8% in black, and 23.9% in other race 
group) of white patients initiated hemodialysis at age 75 years or older. Thus, it is likely that the 
higher PM effect observed among white patients could be driven by the larger proportion of 
white patients that initiated dialysis at an older age. Feng et al. reported a slightly higher long-
term mortality effect among white patients for the area of annual PM2.5 less than 12 µg/m3 but a 
lower effect among white patients when restricted the analysis to area of annual PM2.5 over 12 
µg/m3.(11) Studies in other populations have also reported mixed results by race stratification.(3) 
In addition, this racial mortality hazards variation could be explained by the fact that the baseline 
mortality risks are different across race groups for ESKD patients. In a large cohort study on US 
dialysis patients, Yan et al. observed a consistently higher mortality risk among non-Hispanic 
whites in comparison to Hispanics and non-Hispanic blacks regardless of age.(150) Thus, it is 
not conclusive to determine how race is a modifier for PM2.5 shot-term mortality effect, and more 
studies are needed to determine whether and how race modifies the association for dialysis 





We also observed an un-expected higher hazard among patients with no diabetes at 
baseline. This difference in all-cause and CVD-specific mortalities hazards by baseline diabetes 
status could be partially explained by the fact that more patients with diabetes (50.4% vs. 46.5%) 
initiated dialysis at a younger age (before 65-year old) (Table 4-6). To our knowledge, no study 
has assessed the short-term particulate matter exposure effect by baseline diabetes status among 
dialysis patients. Feng et al.’s study on long-term PM effect, observed a higher risk among 
patients who reported diabetes as primary reason of end-stage kidney disease, which is different 
from baseline diabetes status.(11) Furthermore, studies among general population yields mixed 
and non-significant results regarding the potential modification by diabetes status on PM2.5 
effect.(3, 152-154) Thus, more studies are needed to determine comorbidity specific effect for 
fine particle exposure among dialysis patients. 
This study has several strengths. First, the USRDS database is highly representative of 
hemodialysis patients in the US, with a nearly complete inclusion of those who initiated in-center 
hemodialysis between 2011and 2016 in the US. The USRDS registry provides a complete 
registry of all deaths and healthcare service usages and contains detailed information regarding 
demographics, comorbidities, and dialysis clinic information. Second, linkage of the exposure 
using the dialysis treatment date and ZIP code of dialysis clinic visited enabled the most accurate 
exposure classification we can achieve with the available data. In our study population, more 
than half of the included patients had at least one ZIP code-level change of location during 
follow-up. This suggests that taking location changes into account for exposure linkage is 
necessary to avoid exposure misclassification for this population. Third, we utilized a 
sophisticated model of high spatial and temporal resolution with established accuracy estimating 





discrete time hazards model allowed us to control for individual level time invariant factors 
together with time-varying factors to better estimate the health risk associated with fluctuation in 
ambient PM2.5. This study design also allowed us to assess effect measure modification by 
individual-level factors (e.g. race, age), which are not feasible with time-series study design. 
This study also has some limitations. First, exposure misclassification is always a concern 
in environmental exposure studies as the individual-level exposure is not known. Instead, we 
assumed that the average exposure is similar across patients within in the same ZIP code area 
and that the degree of exposure misclassification does not vary simultaneously with daily 
variation in ZIP code-level exposure and health risks. Second, in this analysis we used 
information on employment at dialysis initiation to classify socio-economic status, which could 
result in some misclassification of SES. Employment at dialysis initiation may not necessarily 
reflect the patients’ SES. However, this is the best information available in our source data. 
Future studies should identify additional source of information or collect information for 
individual SES classification (e.g. income, education) among dialysis patients to better 
understand the potential confounding or modification effect by this factor. Finally, for all 
observational studies there is the possibility of unmeasured confounding (e.g. individual physical 
activity). In the presence of unmeasured confounding, our estimates could not be interpreted as 
causal. 
In conclusion, in this large retrospective open cohort study, we found evidence of short-
term effects of ambient PM2.5 exposure on mortality and CVD outcomes among patients 
receiving maintenance in-center HD. For every 10 units increase in ambient PM2.5 the mortality 
and CVD hazards increased by 3-5%, and the mortality hazards associated with PM2.5 was most 





findings suggest that it is necessary for more studies to develop and implement interventions to 
manage particulate matter exposure in this and other particularly fragile populations. 
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Table 4-1. Study population baseline characteristics overall and by outcomes of interests. 
Characteristics Total 
Mortality  Incidence 
All-Cause  CVD-Specific   CV Event 
n 314,079 82,567 35,857  208,113 
Person-day  193,121,928 193,121,928 193,121,928  94,385,773 
Age at HD 
Initiation (year) 
63.6 (14.6) 69.0 (13.0) 69.4 (13.2) 
 
65.4 (14.0) 
Age at HD Initiation     
18-44 years 34,191 (10.9) 3,803 (4.6) 1,808 (5.0)  17,019 (8.2) 
45-64 years 119,140 (37.9) 23,565 (28.5) 10,759 (30.0)  74,068 (35.6) 
65-74 years 81,741 (26.0) 23,978 (29.0) 10,280 (28.7)  57,125 (27.5) 
75 years and older 79,007 (25.2) 31,221 (37.8) 13,010 (36.3)  59,901 (28.8) 
Vintage (year) 1.9 (1.4) 1.7 (1.2) 1.7 (1.2)  2.2 (1.5) 
Vintage (year)     
Less than 1 year 108,957 (34.7) 32,153 (38.9) 13,596 (37.9)  54,144 (26.0) 
1 – 2 years 81,617 (26.0) 23,347 (28.3) 10,145 (28.3)  55,742 (26.8) 
2 – 3 years 53,198 (16.9) 14,035 (17.0) 6,266 (17.5)  40,457 (19.4) 
3 – 4 years 35,163 (11.2) 8,058 (9.8) 3,644 (10.2)  28,315 (13.6) 
Over 4 years 35,144 (11.2) 4,974 (6.0) 2,206 (6.2)  29,455 (14.2) 
BMI (kg/m2)  29.9 (8.1) 29.0 (8.0) 29.3 (8.0)  29.8 (8.2) 
Female 131,209 (43.9) 36,343 (44.0) 15,244 (42.5)  93,832 (45.1) 
Race      
White 194,790 (65.1) 58,106 (70.4) 25,103 (70.0) 
 136,196 
(65.4) 
Black 88,415 (29.6) 20,071 (24.3) 8,917 (24.9)  60,123 (28.9) 
Other 15,868 (5.3) 4,390 (5.3) 1,837 (5.1)  11,794 (5.7) 
Reported Cause of Kidney Failure    
Diabetes 152,106 (48.4) 40,205 (48.7) 18,734 (52.3) 
 105,544 
(50.7) 
Glomerulonephritis 20,846 (6.6) 3,536 (4.3) 1,368 (3.8)  11,351 (5.5) 
Hypertension 97,204 (31.0) 26,555 (32.2) 11,530 (32.2)  64,554 (31.0) 
Other 43,923 (14.0) 12,271 (14.9) 4,225 (11.8)  26,664 (12.8) 
Access Type      
AVF 54,008 (18.1) 11,094 (13.4) 4,937 (13.8)  32,914 (15.8) 
Graft 9,527 (3.2) 2,427 (2.9) 1,070 (3.0)  6,543 (3.1) 
Catheter 235,042 (78.6) 66,320 (80.3) 28,782 (80.3) 
 159,809 
(76.8) 
Other 496 (0.2) 139 (0.2) 61 (0.2)  327 (0.2) 
Baseline Comorbidities     
CVD 160,760 (53.8) 53,452 (64.7) 24,218 (67.5) 
 123,121 
(59.2) 
COPD 30,417 (10.2) 11,841 (14.3) 5,220 (14.6)  24,067 (11.6) 
Diabetes Mellitus 178,489 (59.7) 49,725 (60.2) 22,728 (63.4) 
 128,114 
(61.6) 
Geographic Region     
Northeast 68,668 (21.9) 20,183 (24.4) 8,831 (24.6)  47,707 (22.9) 





West 40,001 (12.7) 9,091 (11.0) 4,146 (11.6)  24,398 (11.7) 
South 146,167 (46.5) 37,931 (45.9) 16,847 (47.0)  96,603 (46.4) 
Baseline Employment Status     
Employed 30,746 (9.8) 4,621 (5.6) 2,082 (5.8)  15,655 (7.5) 
Retired 196,525 (62.6) 61,159 (74.1) 26,353 (73.5) 
 139,909 
(67.2) 
Unemployed 76,338 (24.3) 15,088 (18.3) 6,793 (10.9)  47,033 (22.6) 
Other 10,470 (3.3) 1,699 (2.1) 629 (1.8)  5,516 (2.7) 
Vintage is defined as the time between hemodialysis initiation and the end of study follow-up, which is death, drop-
out of Medicare, change of modality, or the last day of study period. HD=Hemodialysis, BMI = Body Mass Index, 
AVF = Arteriovenous Fistula, COPD = Chronic obstructive pulmonary disease. 
 
Figure 4-1. Hazard Ratios (95% CI) of short-term ambient PM2.5 exposure (average daily PM2.5 
Lag 0-1) on all-cause mortality, CVD-specific mortality, and CV event among HD patients, 
2011-2016. 
 
The reported effect estimates were obtained from models that adjusted for time since dialysis initiation, temperature, 
relative humidity, day of the week (DOW), season (warm vs cold), age at dialysis initiation, race, employment status 
at dialysis initiation, and geographic region (Northeast, Midwest, South, and West) at dialysis initiation. 
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Figure 4-2. All-cause mortality stratification analysis by age at dialysis initiation, sex, race, and 
comorbidity status at dialysis initiation. Estimates (HRs per 10 µg/m3 increase) of association 
between average daily PM2.5 (Lag 0-1) exposure and all-cause mortality among HD patients, 
2011-2016.  
 
HR = Hazard Ratio, DM = Diabetes Mellitus, COPD = Chronic obstructive pulmonary disease. Effect estimates 
reported for age at dialysis initiation groups were adjusted for: temperature, relative humidity, DOW, season, race, 
employment status, and geographic region. Effect estimates reported for race groups were adjusted for: temperature, 
relative humidity, DOW, season, age at dialysis initiation, employment status, and geographic region. The rest 
estimates were obtained from models that adjusted for: temperature, relative humidity, DOW, season, age at dialysis 






Figure 4-3. CVD-specific mortality stratification analysis by age at dialysis initiation, sex, race, 
and comorbidity status at dialysis initiation. Estimates (HRs per 10 µg/m3 increase) of 
association between average daily PM2.5 (Lag 0-1) exposure and CVD-specific mortality among 
HD patients, 2011-2016. 
 
HR = Hazard Ratio, DM = Diabetes Mellitus, COPD = Chronic obstructive pulmonary disease. Effect estimates 
reported for age at dialysis initiation groups were adjusted for: temperature, relative humidity, DOW, season, race, 
employment status, and geographic region. Effect estimates reported for race groups were adjusted for: temperature, 
relative humidity, DOW, season, age at dialysis initiation, employment status, and geographic region. The rest 
estimates were obtained from models that adjusted for: temperature, relative humidity, DOW, season, age at dialysis 






Figure 4-4. CV event stratification analysis by age at dialysis initiation, sex, race, and 
comorbidity status at dialysis initiation. Estimates (HRs per 10 µg/m3 increase) of association 
between average daily PM2.5 (Lag 0-1) exposure and first CVD event since dialysis initiation 
among HD patients, 2011-2016. 
 
HR = Hazard Ratio, DM = Diabetes Mellitus, COPD = Chronic obstructive pulmonary disease. Effect estimates 
reported for age at dialysis initiation groups were adjusted for: temperature, relative humidity, DOW, season, race, 
employment status, and geographic region. Effect estimates reported for race groups were adjusted for: temperature, 
relative humidity, DOW, season, age at dialysis initiation, employment status, and geographic region. The rest 
estimates were obtained from models that adjusted for: temperature, relative humidity, DOW, season, age at dialysis 








Table 4-2. Cause of death and ICD codes used to identify CV events. 
Event Codes 
CVD related mortality Primary Cause of Death* 
 23, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36 
CVD related emergency 
department visits and 
hospitalization 
ICD-9 ICD-10 
Hypertensive disease 402, 404 I11, I13 
Ischemic heart disease 410, 411, 412, 413, 414 I20, I21, I22, I23, I24, I25. 
Heart failure, cardiac arrest, 
and related 
398, 420, 421, 422, 423, 424, 
425, 426, 427, 428, 429 
I09, I30, I31, I32, I33, I34, 
I35, I36, I37, I38, I39, I40, 
I41, I42, I43, I44, I45, I46, 
I47, I48, I49, I50, I51. 
Cerebrovascular 
430, 431, 432, 433, 434, 435, 
436, 437, 438 
I60, I61, I62, I63, I64, I65, 
I66, I67, I68, I69, G45, G46. 
* The primary cause of death codes are based on the CMS 2746 form list of causes. 
 
Table 4-3. United States, 2011-2016 ZIP code-level daily ambient PM2.5 concentration and 
meteorological data for all person-days included. 
A. Mortality analysis (n = 193,121,928 person-days) 
 Mean (STD) Range Median Q1 Q3 
PM2.5 (µg/m3) 8.5 (4.8) 0,175.3 7.6 5.4 10.6 
Temperature (°C) 15.6 (9.7) -34.7, 41.5  17.1 9.0 23.3 
Relative Humidity (%) 65.7 (15.7) 0, 121.0 67.7 56.7 76.8 
B. CVD event analysis (n = 94,385,773 person-days) 
 Mean (STD) Range Median Q1 Q3 
PM2.5 (µg/m3) 8.6 (4.9) 0, 175.3 7.7 5.4 10.7 
Temperature (°C) 15.6 (9.7) -31.5, 41.5 17.1 9.1 23.3 







Table 4-4. Hazards ratios (95% confidence interval) estimates per 10 µg/m3 increase for the 
association between short-term PM2.5 exposures and all-cause mortality, CVD-specific mortality, 
and CV events among the overall study population. 
Outcome Model Lag HR (95%CI) 
All-cause Mortality Same Day Only Lag 0 1.03 (1.02, 1.05) 
 Lagged  Lag 0 1.01 (0.99, 1.03) 
  Lag 1 1.03 (1.01, 1.06) 
  Lag 2 1.00 (0.97, 1.02) 
  Lag 3 1.00 (0.98, 1.02) 
 Average Lagged  Lag 0-1 1.04 (1.03, 1.06) 
 Average Lagged  Lag 0-2 1.05 (1.03, 1.06) 
 Average Lagged  Lag 0-3 1.05 (1.03, 1.06) 
CVD-specific Mortality Same Day Only Lag 0 1.04 (1.02, 1.07) 
 Lagged  Lag 0 1.02 (0.99, 1.05) 
  Lag 1 1.03 (0.99, 1.07) 
  Lag 2 0.99 (0.96, 1.03) 
  Lag 3 1.01 (0.98, 1.04) 
 Average Lagged  Lag 0-1 1.05 (1.03, 1.08) 
 Average Lagged  Lag 0-2 1.06 (1.03, 1.08) 
 Average Lagged  Lag 0-3 1.06 (1.03, 1.08) 
CV Event Same Day Only Lag 0 1.03 (1.02, 1.04) 
 Lagged  Lag 0 1.02 (1.01, 1.03) 
  Lag 1 1.01 (1.00, 1.03) 
  Lag 2 1.00 (0.98, 1.01) 
  Lag 3 1.00 (0.99, 1.01) 
 Average Lagged  Lag 0-1 1.03 (1.03, 1.04) 
 Average Lagged  Lag 0-2 1.03 (1.02, 1.05) 







Table 4-5. LRT (likelihood ratio test) Test For Homogeneity Results 
Outcome Potential Modifier LRT Test p-value 
All-Cause Mortality Age at Dialysis Initiation <0.01 
 Sex 0.74 
 Race <0.01 
 Baseline DM <0.01 
 Baseline CVD 0.53 
 Baseline COPD 0.58 
CVD-Specific Mortality Age at Dialysis Initiation <0.01 
 Sex 0.81 
 Race <0.01 
 Baseline DM <0.01 
 Baseline CVD 0.29 
 Baseline COPD 0.50 
CV Events Age at Dialysis Initiation 0.37 
 Sex 0.18 
 Race 0.50 
 Baseline DM 1.00 
 Baseline CVD 1.00 







Table 4-6. Study cohort age at dialysis initiation distribution (%) by potential modifiers. 
 Age Categories 
 18-44 45-64 65-74 75-older 
Overall Study Population 10.9 37.9 26.0 25.2 
Baseline CVD     
Yes 5.2 34.0 29.3 31.4 
No 17.1 42.3 22.4 18.2 
Baseline DM     
Yes 8.6 41.8 28.3 21.4 
No 14.1 32.4 22.8 30.6 
Baseline COPD     
Yes 2.2 31.0 34.3 32.6 
No 11.8 38.7 25.1 24.3 
Race     
Black 17.1 45.1 22.1 15.8 
White 8.0 34.5 28.0 29.5 
Other 12.2 39.7 24.3 23.9 
Gender     
Male 11.5 39.6 24.8 24.1 








CHAPTER 5. LONG-TERM PM2.5 EXPOSURE AND DIALYSIS PATIENTS 
INTRODUCTION 
As one of the six National Ambient Air Quality Standards (NAAQS) criteria pollutions, 
ambient particulate matter has been linked with adverse health outcomes in the general 
population.(3) Unlike other pollutants, particles with a mass median aerodynamic diameter of 
less than 2.5 µm (PM2.5) are near-ubiquitous spatially and temporally. The exposure of PM2.5 is 
often sustained over a long period of time. The latest Integrated Scientific Assessment for 
Particulate Matter concluded that there is a causal relationship between long-term exposure to 
PM2.5 and cardiovascular disease (CVD).(3) Thus, even when the current (short-term) PM2.5 
exposure is well-managed, a person can still experience PM2.5 related health impact if he or she 
was exposed to elevated levels of PM2.5 in the past. Due to the fine size, inhaled PM2.5 particles 
can travel deep in the lung and even enter the circulatory system.(143) Animal toxicological, 
controlled human exposure and epidemiologic studies have linked PM2.5 exposure with progress 
from initial events (e.g. local and system inflammation, oxidative stress, autonomic nervous 
system activation) to outcomes of cardiovascular diseases (e.g. stroke, atherosclerosis) and other 
morbidities (e.g. respiratory diseases) and ultimately deaths.(155-158) 
Previous studies have established long-term ambient PM2.5 as a cause of CVD and 
mortality in the general population; however, effects of long-term PM2.5 exposure among people 
who may be particularly susceptible to PM2.5-associated health effects remains understudied.(3) 





key step in reducing the public health burden of PM2.5 exposure. Patients with kidney failure who 
require maintenance in-center hemodialysis (HD) treatment are a fragile population with 
multiple pre-existing conditions.(6) HD patients have a high burden of CVD, and the relative risk 
of death due to cardiovascular (CV) events in HD patients is 20 times higher than that of the 
general population.(8) HD patients also experience high mortality rates; the annual mortality rate 
was 16% in 2018 among US hemodialysis patients.(6) This population could be particularly 
susceptible to the adverse effects of long-term PM2.5 exposure, yet, to our knowledge, the long-
term PM2.5 exposure effect on CVD outcomes has not been studied among HD patients. 
We assessed the association between long-term PM2.5 exposure and CV event and CVD-
specific mortality among patients receiving in-center hemodialysis in the contiguous United 
States. Potential effect measure modifications by age, sex, race, and baseline comorbidities were 
also assessed to further identify specifically susceptible groups within HD patients. 
METHODS 
Study Setting and Study Population 
We identified a retrospective cohort of maintenance HD patients from the United States 
Renal Data System (USRDS), a claim-based national registry of patients with kidney failure. 
USRDS includes nearly all dialysis patients in the United States.(6) We extracted baseline 
demographic characteristics, dialysis treatment, and comorbidity for adult (aged 18 years or 
older) patients who initiated in-center hemodialysis treatment between January 1, 2011 and 
December 31, 2016 in the contiguous U.S. who had Medicare as their primary payer. Participants 
were followed from the fourth month of dialysis initiation (i.e., time of Medicare coverage 





peritoneal dialysis, kidney transplant), loss of Medicare coverage, death, or end of study follow-
up (Dec 31, 2016).  
Exposure Assessment and Meteorological Data 
For each participant-day under follow-up, a daily record of location, at the ZIP code-
level, was assigned based on the ZIP code of the dialysis clinic visited during that period of time. 
Patients typically visited a dialysis clinic every 2 or 3 days. It has been reported that patients in 
the USRDS cohort who received maintenance in-center dialysis travel a median distance of 5.7 
miles from their homes to their dialysis clinics.(136, 137)  For a date between claim filing 
periods, with no information on clinic visits, the ZIP code of the last clinic visited was assigned 
to capture possible location change of hemodialysis patient (1.3% of the person-days in the 
mortality analysis had a ZIP code that was different from the previous person-day of the same 
individual).  
We linked PM2.5 exposure to person-day records and weather variables based on date and 
ZIP code of the (last) dialysis clinic visited. For outcomes which occurred within one year of 
dialysis initiation, the first available dialysis clinic ZIP code was used for the days prior to 
dialysis initiation for exposure linkage and long-term exposure calculation. The maximum look-
back period pre-dialysis initiation would be 9 months if the outcome occurred on the first day of 
follow-up start, which is the first day of the fourth month of dialysis initiation. 
ZIP code-level daily PM2.5 concentrations were estimated with a previously described 
prediction model.(115, 117, 159) In brief, this model estimates daily PM2.5 on a 1 km grid for the 
entire continental US by incorporating satellite aerosol optical depth measurements, chemical 
transport model simulations, meteorology, land use and other factors. Gridded PM2.5 estimates 





population values. Long-term exposure was defined as the annual average of daily PM2.5 level 
across the year (365 days) prior to the outcome, which was calculated by averaging the daily 
PM2.5 concentrations across 365-day period for each patient taking potential ZIP-code level 
change of location into account. Annual average of daily PM2.5 has been used widely to define 
long-term PM exposure in previous studies, furthermore, both NAAQS and World Health 
Organization set standards for long-term PM2.5 on this scale.(39, 160) 
Daily temperature and relative humidity data were obtained from the US National 
Oceanic and Atmospheric Administration (NOAA). Specifically, daily temperature and relative 
humidity from weather station measurements were interpolated to census tract centroids and then 
averaged over tracts to ZIP codes.  
Outcome Assessment 
Follow-up to ascertain CV events and CVD-related deaths through December 21, 2016 
was based on USRDS records. The outcomes of interest were CV event and CVD-specific 
mortality. The primary cause of death recorded in ESRD Death Notification Form (CMS 2746) 
was used to classify mortality into CVD-specific mortalities. We defined CV event as the first 
CVD-related emergency department (ED) visit, hospitalization, or morality, which ever occurred 
first since the beginning of follow-up. International Classification of Disease, 9th and 10th 
Revision (ICD-9, ICD-10) codes were used to identify cause-specific ED visits and 
hospitalization. In brief, any ED visit and hospitalization with a code indicating cerebrovascular, 
ischemic heart disease, hypertensive disease, heart failure, cardiac arrest, and related events were 
classified as CVD related ED and HA events. The cause of death codes and International 







We utilized discrete time hazards models to assess the association between ZIP code-
level long-term PM2.5 exposure with CV events and CVD-specific mortality.(138) Discrete time 
hazards models have been widely used in occupational and environmental cohort studies. This 
approach is similar to a Poisson regression approach applied to a person-period data structure, 
which allows controlling for individual level factors.(138) The equation for the fully-adjusted 
model is presented in Equation 1, where Y is the individual specific response at time t (e.g. 0 if 
no death, 1 death…), and i, t, indexes individual, and time (day), respectively. We used a 
generalized linear model E(Yit| covariates) = g^{-1}(𝜂𝑖𝑡) with a complimentary log-log link 
function g and a linear predictor 𝜂𝑖𝑡 as follows: 
𝑙𝑜𝑔 (−log (1 − 𝐸(𝑌𝑖𝑡|𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)) = 𝜂𝑖𝑡
=  𝑀𝑜𝑛𝑡ℎ𝑆𝑖𝑛𝑐𝑒𝐷𝑖𝑎𝑙𝑦𝑠𝑖𝑠𝑚(𝑖𝑡) + 𝛽1𝐴𝑛𝑛𝑎𝑢𝑙𝐴𝑣𝑒𝑟𝑎𝑔𝑒𝑃𝑀2.5𝑖𝑡
+ 𝛽2𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒𝑖𝑡 + 𝛽3𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝐻𝑢𝑚𝑖𝑑𝑖𝑡𝑦𝑖𝑡 + 𝛽4𝐷𝑂𝑊𝑖𝑡 + 𝛽5𝑆𝑒𝑎𝑠𝑜𝑛𝑖𝑡
+ 𝛽6𝐴𝑔𝑒(𝑑𝑖𝑎𝑙𝑦𝑠𝑖𝑠 𝑖𝑛𝑖𝑡𝑖𝑎𝑡𝑖𝑜𝑛)𝑖 + 𝛽7𝑅𝑎𝑐𝑒𝑖 + 𝛽8𝐸𝑚𝑝𝑙𝑜𝑦𝑚𝑒𝑛𝑡𝑆𝑡𝑎𝑡𝑢𝑠𝑖
+ 𝛽9𝑅𝑒𝑔𝑖𝑜𝑛𝑖 
Equation 1 
Variables DOW (day of week), Season, Race, Region and Employment status were categorical 
thus the coefficients represent vectors rather than scalars. Hazard ratios (HRs) per 1-µg/m3 
increase in PM2.5, together with corresponding 95% confidence intervals (95% CIs) were 
estimated. We incorporated time since the initiation of dialysis as the analysis time scale to 
control for the potential temporal effect variation by this factor, which has been suggested to be a 
predictor of mortality and comorbidities among dialysis patients.(139, 140) Daily temperature, 





for potential time varying confounding. Specifically, DOW and season were incorporated to 
account for short- and long-term temporal variability of the outcomes.(141, 142) Time-invariant 
confounders included age at dialysis initiation, race, baseline employment status, and geographic 
region (Northeast, Midwest, South, and West). Baseline employment status was incorporated as 
a surrogate for socio-economic status (SES) as classical SES variables like income or education 
level information were not available.  
Potential effect measure modifications by baseline comorbidity statuses, race, sex, and 
dialysis initiating age were assessed. The comorbidities assessed were diabetes, CVD, and 
chronic obstructive pulmonary disease (COPD) reported at the start of maintenance hemodialysis 
on the CMS 2728 form. Specifically, the patients who were reported to have any of the following 
conditions: atherosclerotic heart disease, cardiac arrest, congestive heart failure, cerebrovascular 
disease, cardiac dysrhythmia, ischemic heart disease, myocardial infarction, pericarditis, 
peripheral vascular disease, and other cardiac disease, were classified as having CVD at baseline. 
The patients who were reported to have diabetes (primary or contributing), who were diabetic 
and currently on insulin, on oral medications, or without medications, or with diabetic 
retinopathy were classified as having diabetes at baseline. The patients who were reported to 
have chronic obstructive pulmonary disease were classified to have COPD at baseline. 
Likelihood ratio tests for homogeneity were performed by comparing models with and without 
an interaction term between the potential modifier and PM term. A small Chi-square test of 
likelihood ratios test p-value (less than 0.05) was used to reject the null hypothesis of 








To assess for the potential variation of effect by different definitions (time windows) of 
long-term PM2.5 exposure, we assessed the effect of 6-month- and 2-year- average of daily PM2.5 
in addition to the annual average. The effect of long-term PM2.5 exposure on all-cause mortality 
was also assessed. 
Data management and statistical analysis were performed using SAS software, Version 
9.4 (SAS Institute Inc., Cary, NC, USA). Plots were generated with R Project for Statistical 
Computing Version 3.5.0 (R Foundation for Statistical Computing, Vianna, Austria).  The study 
protocol was reviewed and exempted by the Institutional Review Board of the University of 
North Carolina on Nov 16, 2020 (Study #:20-1469). 
RESULTS 
The final cohort included a total of 314,079 hemodialysis patients with 193,121,928 
person-days of follow-up in the mortality analyses and 94,385,773 person-days in the CV event 
analysis. Between 2011 and 2016, there were 35,857 (43.4% out of total all-cause mortality) 
CVD-related mortalities, and 208,113 patients experienced at least one CV event. Table 5-1 
displays the study population characteristics. More than half of the participants were older than 
65 years of age at the initiation of hemodialysis. The average time on hemodialysis was 1.9 
(STD=1.4) years. Approximately 44% of the study participants were female, and 65% were 
white. At hemodialysis initiation, more than half of the cohort had diabetes, about 60% had 
CVD, and 10% had COPD. 
Table 5-2 displays the distribution of long-term ambient PM2.5 concentrations. The 
median annual-average ambient PM2.5 for the mortality analysis was 8.7 (inter-quartile range: 





identical to that of the mortality analysis with a median of 8.8 (IQR: 2.3) µg/m3. The average 
long-term PM2.5 was slightly higher when longer time windows were used to define long-term 
exposure (Table 5-2.) The distributions of meteorology variables (daily relative humidity and 
temperature) are presented in Table 5-4. 
Overall, increases in long-term ambient PM2.5 were associated with increased hazards of 
CV event and CVD-specific mortality (Figure 5-1). The effects were slightly higher when longer 
time windows were used to define the exposure, but the 95% confidence intervals were 
overlapping and, therefore, the long-term effect are robust against different long-term exposure 
definitions assessed (Figure 5-1). Annual-average PM2.5 was reported as the primary exposure of 
interest for the robustness of effect regardless of average time window. The HRs associated with 
every 1 µg/m3 increase in annual average PM2.5 for CV event and CVD-specific mortality were 
1.012 (95% CI: 1.010, 1.015) and 1.015 (95% CI: 1.009, 1.021), respectively (Figure 5-1). 
For CV events, the effect of PM2.5 was relatively higher among hemodialysis patients 
who started dialysis in the oldest age group (≥75 years), those who were female, and those with 
COPD at dialysis initiation (Figure 5-2). The HR of 1.020 (95%CI: 1.015, 1.024) associated with 
every 1-µg/m3 increase in annual-average PM2.5 was observed among HD patients who initiated 
dialysis at the age of 75-year or older (Figure 5-2). For HD patients who reported to have COPD 
at dialysis initiation, the HR of 1.024 (95% CI: 1.016, 1.031) was estimated (Figure 5-2). The 
HR estimate was higher for female patients with overlapping confidence intervals comparing to 
male patients (Female HR: 1.014 95%: CI, 1.010, 1.018; Male HR: 1.011, 95%CI: 1.008, 1.014) 
(Figure 5-2). The likelihood ratio test for homogeneity also suggested the PM effects on CV 
event were not similar across different levels of dialysis initiating age, sex, and baseline COPD 





For CVD-specific mortality, hemodialysis patients who started dialysis in the oldest age 
group, were of white or other race, and did not have diabetes or had COPD at dialysis initiation 
experienced relatively higher PM effect compared to other groups (Figure 5-3). The highest HR 
of 1.042 (95% CI: 1.032, 1.052) associated with every 1-µg/m3 increase in annual-average PM2.5 
was observed among HD patients who initiated dialysis at the age of 75-year or older (Figure 5-
3). For HD patients with COPD at dialysis initiation, the HR was 1.025 (95% CI: 1.009, 1.042) 
with overlapping confidence intervals of the HR estimated among patients with no baseline 
COPD (Figure 5-2). The likelihood ratio test for homogeneity also suggested the PM effect on 
CVD-specific mortality are not similar across different levels of dialysis initiating age, race, 
baseline diabetes status, and baseline COPD status (Table 5-5). 
DISCUSSION 
We estimated the associations between long-term PM2.5 and CV events and CVD-specific 
mortality, separately, among US hemodialysis patients during the period 2011-2016. Long-term 
PM2.5 exposure was associated with higher hazards for both studied outcomes in this vulnerable 
population. Each 1 µg/m3 increase in annual-average PM2.5 was associated with a 1.2% and 1.5% 
increase in the hazard of CV event and CVD-specific mortality, respectively. We also observed 
relatively higher PM2.5 hazards for both outcomes among hemodialysis patients who initiated 
dialysis at an older age and who had COPD at dialysis initiation. In addition, we observed higher 
PM2.5 hazards for CVD-specific mortalities among HD patients who did not have diabetes 
mellitus at dialysis initiation. Furthermore, the long-term effect of PM2.5 exposure on CVD-
specific mortality was higher among non-black race groups. 
There is emerging evidence on the effect of PM2.5 exposure on maintenance dialysis 





effect on CVD outcomes among US dialysis patients. We observed an elevated risk of CV event 
associated with long-term PM2.5 exposure which is consistent with a study among HD patients on 
the association between CVD-related hospitalization and county-level short-term PM2.5.(103) 
Wyatt et al. reported a 0.9% (95% CI, 0.4%, 1.8%) increase in hospital admission risk for 
cardiovascular causes for the same-day county-level PM2.5 exposure in the US.(103) Our 
findings add to the evidence that particulate matter is associated with adverse cardiovascular 
outcomes. However, it was unexpected that the effect size observed for CV events was slightly 
lower than that of CVD-specific mortality (1.2% vs. 1.5% increases in HRs , albeit with 
overlapping confidence intervals) as it is logical that a person would develop an incident CV 
event before their death. A possible explanation may be due to the different diagnosis coding 
algorithms used to define CVD-specific mortality vs. CV event. Specifically, CVD-related 
mortality was defined using CMS 2746 form codes, which do not directly correspond to ICD-9 
or -10 codes for CV events identification; indeed, future studies should identify and use 
additional data sources on cause of death. This could also be due to the fact that CVD prevalence 
was high in the cohort since the start of study follow up. Thus, for those with prevalent CVD, 
they would die from CVD conditions without cardiovascular disease associated ED visit or 
hospitalization. Another plausible explanation is that long-term PM2.5 exposure could impact the 
CVD case fatality rate, which could be assessed in future studies instead of first CV event since 
follow-up to take all CVD incidences into account. In addition, we also recognize that the 
baseline CV event and CVD-specific mortality risks were likely different by baseline CVD 
status. However, we didn’t observe significantly different hazards among people with and 





We observed an elevated health risk associated long-term PM2.5 exposure among 
hemodialysis patients, which is consistent with the findings of a recent study by Feng et al.(11) 
However, Feng et al. focused on all-cause mortality among older (over 65) US both hemodialysis 
and peritoneal dialysis patients, a different study population from ours.(11) They also reported 
effects per 10 µg/m3 increase in annual-average PM2.5 for all-cause mortality, and we reported 
effects per 1 µg/m3 increase in annual-average PM2.5 as it is rare to observe a 10 µg/m3 increase 
in annual-average PM2.5 in real world (the IQR for the entire study period was 2.2-2.3 µg/m3). 
We performed additional analysis on all-cause mortality and yield similar effects estimates 
comparing to Feng et al. (Table 5-6).(11) For CVD mortality, they reported a similar but slightly 
higher HR of 1.38 (95% CI, 1.21, 1.58) per 10 µg/m3 increase for annual-average PM2.5 above 12 
µg/m3.22 The slightly higher effects reported by Feng et al. could be potentially explained by the 
fact that they restricted their analysis to the older (over 65-year old) dialysis patients, who could 
be more susceptible towards long-term PM2.5 exposure. Another recent study among Hong Kong 
renal failure patients also observed PM2.5 exposure’s impact on mortality.(161) Together with the 
previously published studies, our findings support the conclusion that long-term exposure to 
particulate matter, even when at relatively low levels, is associated with elevated hazard of CVD 
outcomes among patients with kidney failure. 
Our findings suggest that there is larger magnitude of association between long-term 
PM2.5 exposure and all three outcomes among patients who initiated dialysis treatment at an 
older age and who had COPD at dialysis initiation. Among different age groups, the highest 
PM2.5 effects were observed among patients who initiate dialysis at the age of 75 or older, which 
is the oldest group. This effect modification observed could be explained by the higher 





observed a higher long-term PM2.5 exposure effect on all-cause mortality among dialysis patients 
who aged 75 years or over at dialysis initiation compared to those who initiated dialysis 65-74 
years old. Even though Feng et al.’s study population and study outcome were different from our 
analysis by including peritoneal dialysis patients, our findings agrees that kidney disease patients 
who initiated dialysis at the age of 75 or older were likely to be particularly susceptible to PM 
exposure. To our knowledge, no study has assessed PM effect by COPD status among dialysis 
patients. We observed a 1% additional hazard increase for patients who reported to have COPD 
for all three outcomes compared to the patients who didn’t report to have this condition at 
dialysis initiation. COPD is one of the most common chronic respiratory diseases in the US, and 
it contributes to compromised respiratory function and underlying pulmonary inflammation, 
which potentially leads to susceptibility of air pollutions.(162, 163)  A limited number of studies 
have examined differential risk by COPD status in the general population. Wang et al. reported 
elevated mortality risk associated with annual PM2.5 exposure for those with COPD in a large 
cohort of Medicare beneficiaries residing in the southeastern US states.(39) Studies for 
cardiovascular events yielded inconsistent results regarding whether people with COPD are at a 
higher risk.(163-166) Thus, dialysis patients with COPD are likely to be at higher risk for CVD 
outcomes regarding long-term PM2.5 exposure but more studies are needed to conclude. 
We also observed some potential effect measure modifications by baseline diabetes 
status, and race for long-term PM2.5 exposure. Unexpected higher hazards among patients 
without diabetes at dialysis initiation were observed for CVD-specific mortality. This differential 
in mortalities effects by baseline diabetes status could be potentially explained by the fact that 
more patients with diabetes (50.4% vs. 46.5%) initiated dialysis at a younger age (before 65-year 





diabetes status among dialysis patients. Furthermore, studies among the general population yield 
mixed or non-significant results regarding the potential modification by diabetes status on PM2.5 
effect.(3, 152-154) Thus, more studies are needed to determine if diabetes status modifies the 
fine particle exposure effect among dialysis patients. 
For CVD-specific mortality, we observed a higher effect among white and other race 
compare to black race group. This difference association by race could be partially explained by 
differences in age distribution of dialysis patients by race (Table 5-7). About 29.5% and 23.9% 
(15.8% in black) of white and other race patients initiated hemodialysis at age 75 years or older, 
respectively. Thus, it is likely that the stronger PM2.5 effect observed among white and other 
patients could be driven by the larger proportion of patients that initiated dialysis at an older age. 
Feng et al. also reported a slightly higher long-term mortality effect among white dialysis 
patients for the area of annual PM2.5 less than 12 µg/m3. In addition, this variation in mortality 
hazards by race could be partially explained by the fact that the baseline mortality risks are 
different across race groups for dialysis patients. In a large cohort study on US dialysis patients, 
Yan et al. observed a higher mortality risk among non-Hispanic whites comparing to other race 
groups regardless of age.(150) Furthermore, studies in the general or other populations have also 
reported mixed results on race stratification for PM effects. Thus, it is not conclusive to 
determine if and how race and ethnicity modifies the long-term PM effect among dialysis 
patients as a social factor. 
This study had several strengths. First, the USRDS database is highly representative of 
US hemodialysis patients, with a nearly complete inclusion of those who initiated in-center 
hemodialysis between 2011-2016. This national registry provides a complete registry of all 





comorbidities, and dialysis clinic information. Second, linkage of the PM2.5 concentrations using 
the dialysis treatment date and ZIP code of dialysis clinic visited enabled the best exposure 
classification we can achieve with the available data. In our study population, more than half of 
the included patients had at least one ZIP code-level change of location during follow-up. This 
suggests that taking location changes into account for exposure linkage is necessary to avoid 
potential exposure misclassification for this population. Third, the ZIP code-level daily PM2.5 
concentrations were estimated with a sophisticated model of high spatial and temporal resolution 
with proven accuracy.(115, 117) Last, the use of discrete time hazards models allowed for 
controlling for individual level time invariant factors together with time-varying factors to better 
estimate the health risk associated with fluctuation in ambient PM2.5. In addition, this study 
design allowed us to assess effect measure modification by individual-level factors (e.g. race, 
age), which is not plausible with traditional time-series study on an aggregated level. 
This study also had some limitations. First, exposure misclassification is often a concern 
in environmental exposure studies as the individual-level exposure measurement is not available. 
Instead, the assumption is made that the average exposure is similar across patients within in the 
same ZIP code area and that the degree of exposure misclassification does not vary 
simultaneously with daily variation in ZIP code-level exposure and health risk. Second, in this 
analysis socio-economic status (SES) was classified with the employment status at dialysis 
initiation, which could lead to inaccurate classification of SES. Employment at dialysis initiation 
may not necessarily reflect the patients’ SES. For example, a great proportion of our study 
population were retired at the time of dialysis initiation. However, this is the best information 
available in our source data. Future study should identify additional source of information and/or 





the potential confounding or modification effect by this factor for dialysis patients. Finally, for 
all observational studies there is the possibility of unmeasured confounding (e.g., physical 
activity pattern). In the presence of unmeasured confounding, our estimates should not be 
interpreted as causal. 
In conclusion, in this large retrospective open cohort study, we found evidence of short-
term effects of ambient PM2.5 exposure on CVD outcomes among patients receiving maintenance 
in-center HD. Furthermore, the annual-average ZIP code-level PM2.5 for the majority (Q3 of 9.8 
µg/m3) of the included person-days in this analysis were below the current NAAQS regulatory 
standard of 12 µg/m3. However, the PM concentration in many highly-populated urban areas still 
exceeds the NAAQS standard, and extreme events like wildfires also lead to high-level 
exposures despite the fact that the national level ambient PM2.5 concentration has decreased 39% 
between 2000 and 2018.33,(167) Our findings of elevated hazards of CVD hazard suggest that 
lowering the ambient PM2.5 concentration and exposure management on the individual-level 
could be beneficial to at risk individuals. These findings suggest that it is necessary for more 
studies to develop and implement interventions to manage long-term particulate matter exposure 
in this and other particularly fragile populations. 
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CV Event  
n 314,079 35,857  208,113 
Person-day n 193,121,928 193,121,928  94,385,773 
Age at HD 
Initiation (year) 
63.6 (14.6) 69.4 (13.2) 
 
65.4 (14.0) 
Age at HD Initiation    
18-44 34,191 (10.9) 1,808 (5.0)  17,019 (8.2) 
45-64 119,140 (37.9) 10,759 (30.0)  74,068 (35.6) 
65-74 81,741 (26.0) 10,280 (28.7)  57,125 (27.5) 
75 and older 79,007 (25.2) 13,010 (36.3)  59,901 (28.8) 
Vintage (year) 1.9 (1.4) 1.7 (1.2)  2.2 (1.5) 
Vintage (year)    
Less than 1 year 108,957 (34.7) 13,596 (37.9)  54,144 (26.0) 
1 – 2 81,617 (26.0) 10,145 (28.3)  55,742 (26.8) 
2 – 3 53,198 (16.9) 6,266 (17.5)  40,457 (19.4) 
3 - 4 35,163 (11.2) 3,644 (10.2)  28,315 (13.6) 
Over 4 35,144 (11.2) 2,206 (6.2)  29,455 (14.2) 
BMI (kg/m2)  29.9 (8.1) 29.3 (8.0)  29.8 (8.2) 
Female 131,209 (43.9) 15,244 (42.5)  93,832 (45.1) 
Race     
White 194,790 (65.1) 25,103 (70.0)  136,196 (65.4) 
Black 88,415 (29.6) 8,917 (24.9)  60,123 (28.9) 
Other 15,868 (5.3) 1,837 (5.1)  11,794 (5.7) 
Reported Cause of ESKD    
Diabetes 152,106 (48.4) 18,734 (52.3)  105,544 (50.7) 
Glomerulonephritis 20,846 (6.6) 1,368 (3.8)  11,351 (5.5) 
Hypertension 97,204 (31.0) 11,530 (32.2)  64,554 (31.0) 
Other 43,923 (14.0) 4,225 (11.8)  26,664 (12.8) 
Access Type     
AVF 54,008 (18.1) 4,937 (13.8)  32,914 (15.8) 
Graft 9,527 (3.2) 1,070 (3.0)  6,543 (3.1) 
Catheter 235,042 (78.6) 28,782 (80.3)  159,809 (76.8) 
Other 496 (0.2) 61 (0.2)  327 (0.2) 
Baseline Comorbidities    
CVD 160,760 (53.8) 24,218 (67.5)  123,121 (59.2) 
COPD 30,417 (10.2) 5,220 (14.6)  24,067 (11.6) 
Diabetes Mellitus 178,489 (59.7) 22,728 (63.4)  128,114 (61.6) 
Geographic Region    
Northeast 68,668 (21.9) 8,831 (24.6)  47,707 (22.9) 
Midwest 59,243 (19.9) 6,033 (24.6)  39,405 (18.9) 
West 40,001 (12.7) 4,146 (11.6)  24,398 (11.7) 
South 146,167 (46.5) 16,847 (47.0)  96,603 (46.4) 
Baseline Employment Status    





Retired 196,525 (62.6) 26,353 (73.5)  139,909 (67.2) 
Unemployed 76,338 (24.3) 6,793 (10.9)  47,033 (22.6) 
Other 10,470 (3.3) 629 (1.8)  5,516 (2.7) 
Vintage is defined as the time between hemodialysis initiation and the end of study follow-up, which is death, drop-
out of Medicare, change of modality, or the last day of study period. HD=Hemodialysis, BMI = Body Mass Index, 
AVF = Arteriovenous Fistula, COPD = Chronic obstructive pulmonary disease. 
 
Table 5-2. United States, 2011-2016 ZIP code-level long-term PM2.5 concentrations for all 
person-days included by mortality and CV event analysis. 
A. Mortality analysis (n = 193,121,928 person-days) 
PM2.5 (µg/m3) Mean (STD) Range Median Q1 Q3 
Annual Average  8.7 (1.8) 0.9, 21.3 8.7 7.6 9.8 
6-Month Average 8.6 (2.0) 0.8, 31.6  8.5 7.4 9.8 
2-Year Average 8.9 (1.8) 1.3, 20.4 9.0 7.9 10.0 
B. CV event analysis (n = 94,385,773 person-days) 
PM2.5 (µg/m3) Mean (STD) Range Median Q1 Q3 
Annual Average  8.7 (1.9) 0.9, 21.3 8.8 7.6 9.9 
6-Month Average 8.6 (2.1) 0.8, 31.6 8.6 7.4 9.8 







Figure 5-1. Effect (HR and 95% CI) of long-term ambient PM2.5 exposures on CV event and 
CVD-specific mortality among HD patients, 2011-2016. 
 
All effect estimates reported here were obtained from models that adjusted for time since dialysis initiation, 
temperature, relative humidity, day of the week (DOW), season, age at dialysis initiation, race, employment status at 
dialysis initiation, and geographic region (Northeast, Midwest, South, and West) at dialysis initiation. 
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Figure 5-2.  CV event stratification analysis by age at dialysis initiation, sex, race, and 
comorbidity status at dialysis initiation. Estimates (HRs per 1 µg/m3 increase) of association 
between annual average PM2.5 exposure and first CV event since dialysis initiation among HD 
patients, 2011-2016.  
 
HR = Hazard Ratio, DM = Diabetes Mellitus, COPD = Chronic obstructive pulmonary disease. Effect estimates 
reported for age at dialysis initiation groups were adjusted for: temperature, relative humidity, DOW, season, race, 
employment status, and geographic region. Effect estimates reported for race groups were adjusted for: temperature, 
relative humidity, DOW, season, age at dialysis initiation, employment status, and geographic region. The rest 
estimates were obtained from models that adjusted for: temperature, relative humidity, DOW, season, age at dialysis 






Figure 5-3. CVD-specific mortality stratification analysis by age at dialysis initiation, sex, race, 
and comorbidity status at dialysis initiation. Estimates (HRs per 1 µg/m3 increase) of association 
between annual average PM2.5 exposure and CVD-specific mortality among HD patients, 2011-
2016. 
 
HR = Hazard Ratio, DM = Diabetes Mellitus, COPD = Chronic obstructive pulmonary disease. Effect estimates 
reported for age at dialysis initiation groups were adjusted for: temperature, relative humidity, DOW, season, race, 
employment status, and geographic region. Effect estimates reported for race groups were adjusted for: temperature, 
relative humidity, DOW, season, age at dialysis initiation, employment status, and geographic region. The rest 
estimates were obtained from models that adjusted for: temperature, relative humidity, DOW, season, age at dialysis 







Table 5-3. Cause of death and ICD codes used to identify CV events. 
Event Codes 
CVD related mortality Primary Cause of Death* 
 23, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36 
CVD related ED visits and 
hospital admission 
ICD-9 ICD-10 
Hypertensive disease 402, 404 I11, I13 
Ischemic heart disease 410, 411, 412, 413, 414 I20, I21, I22, I23, I24, I25. 
Heart failure, cardiac arrest, 
and related 
398, 420, 421, 422, 423, 424, 
425, 426, 427, 428, 429 
I09, I30, I31, I32, I33, I34, 
I35, I36, I37, I38, I39, I40, 
I41, I42, I43, I44, I45, I46, 
I47, I48, I49, I50, I51. 
Cerebrovascular 
430, 431, 432, 433, 434, 435, 
436, 437, 438 
I60, I61, I62, I63, I64, I65, 
I66, I67, I68, I69, G45, G46. 







Table 5-4. United States, 2011-2016 ZIP code-level daily meteorological variables distribution. 
A. Mortality analysis (n = 193,121,928 person-days) 
 Mean (STD) Range Median Q1 Q3 
Temperature (°C) 15.6 (9.7) -34.7, 41.5  17.1 9.0 23.3 
Relative Humidity (%) 65.7 (15.7) 0, 121.0 67.7 56.7 76.8 
B. CV event analysis (n = 94,385,773 person-days) 
 Mean (STD) Range Median Q1 Q3 
Temperature (°C) 15.6 (9.7) -31.5, 41.5 17.1 9.1 23.3 







Table 5-5. LRT for homogeneity test results for long-term PM2.5 exposure 
Outcome Potential Modifier LRT Test p-value 






Baseline DM <0.01 
 
Baseline CVD 0.92 
 
Baseline COPD 0.05 






Baseline DM 0.24 
 
Baseline CVD 0.48 
 








Table 5-6. All-cause mortality overall and stratification analysis by age at dialysis initiation, sex, 
race, and comorbidity status at dialysis initiation. Estimates (HRs per 1 µg/m3 increase) of 
association between annual average PM2.5 exposure and all-cause mortality among HD patients, 
2011-2016.  
Cohort HR (95%CI) 
Age at Dialysis Initiation LRT p-value: <0.01 
18-44 0.983 (0.965, 1.001) 
45-64 0.999 (0.992, 1.006) 
65-74 1.011 (1.004, 1.018) 
75-over 1.034 (1.028, 1.041) 
Sex LRT p-value: 1 
Female 1.014 (1.008, 1.020) 
Male 1.016 (1.010, 1.021) 
Race LRT p-value: 0.3 
Black 1.015 (1.005, 1.025) 
White 1.014 (1.010, 1.019) 
Other 1.009 (0.994, 1.024) 
Baseline DM LRT p-value: <0.01 
yes 1.009 (1.004, 1.014) 
no 1.023 (1.016, 1.029) 
Baseline CVD LRT p-value: 1 
yes 1.017 (1.012, 1.022) 
no 1.017 (1.011, 1.024) 
Baseline COPD LRT p-value: 0.08 
yes 1.023 (1.012, 1.034) 
no 1.016 (1.011, 1.020) 
  






Table 5-7. Study cohort age at dialysis initiation distribution (%) by potential modifiers (baseline 
comorbidities, race, and gender). 
 Age Categories 
 18-44 45-64 65-74 75-older 
Overall Study Population 10.9 37.9 26.0 25.2 
Baseline CVD     
Yes 5.2 34.0 29.3 31.4 
No 17.1 42.3 22.4 18.2 
Baseline DM     
Yes 8.6 41.8 28.3 21.4 
No 14.1 32.4 22.8 30.6 
Baseline COPD     
Yes 2.2 31.0 34.3 32.6 
No 11.8 38.7 25.1 24.3 
Race     
Black 17.1 45.1 22.1 15.8 
White 8.0 34.5 28.0 29.5 
Other 12.2 39.7 24.3 23.9 
Gender     
Male 11.5 39.6 24.8 24.1 









CHAPTER 6. PM2.5 EXPOSURE AND INFLAMMATION BIOMARKERS 
INTRODUCTION 
Ambient exposure PM2.5 (particles with a mass median aerodynamic diameter of less than 
2.5 µm) exposure is ubiquitous, and it is an established cause of respiratory, cardiovascular 
diseases and mortality.(3) Previous studies have linked PM2.5 particles to inflammation (both 
systemic and local) and other mechanisms that could eventually lead to adverse health outcomes 
including death.(23-26, 28, 71) However, the exact pathological mechanism of PM2.5 exposure 
remains not fully understood. 
Our previous analyses have observed elevated cardiovascular disease (CVD) and 
mortality risk associated with both short- and long- term PM2.5 exposure among kidney failure 
patients requiring in-center hemodialysis (HD) in the US. HD patients experience high CVD and 
mortality risk, and US dialysis patients have an annual all-cause mortality risk of 16% in the year 
of 2018.(6, 8, 81, 83, 144) They are also known for a high prevalence of inflammation 
comparing to the general population.(100, 101) Due to their frailty and the need for treatment 
effect monitoring, HD patients’ health conditions are closely monitored by frequent 
measurements of a variety of biomarkers at the dialysis center before, during or after dialysis 
sessions. Data on those repeatedly measured biomarkers present a unique opportunity to study 
PM2.5’s effect on changes of those markers, which could potentially reveal the plausible 





Among all of the biomarkers frequently measured for HD patients, we selected a group of 
markers for their correlation with health outcomes, linkage to PM exposure, and availability. 
Serum albumin level is an important index for nutrition status and treatment effect of dialysis 
patients, low serum albumin is an indicator for inflammation, infection, and other conditions.(88, 
89) Serum ferritin, an iron storage protein, is also closely monitored, and high serum ferritin 
level has been linked to inflammation.(30, 90-92) Transferrin saturation (TSAT) is a marker of 
iron availability for erythropoiesis, and low TSAT indicates iron deficiency which is prevalent 
among dialysis patients.(93, 94) Low hemoglobin is an indicator for anemia which is closely 
related to inflammation among kidney disease patients, and previous study have linked anemia 
with PM exposure in different populations.(95-97, 168) Blood pressure is closely monitored 
before, during, and after dialysis sessions, and previous studies have linked PM exposure with 
changes in blood pressure in the general population.(98, 99) With this study, we aimed to utilize 
frequently measured biomarkers collected among kidney failure patients who receive in-center 
hemodialysis (HD) in the US to assess the impact of short-term PM2.5 exposure on serum 
albumin, serum ferritin, transferrin saturation (TSAT), hemoglobin, and blood pressures in the 
purpose of providing insights on PM’s plausible pathological mechanism. 
METHODS 
Study Setting and Study Population 
We constructed a retrospective cohort of US patients receiving in-center hemodialysis 
from the dialysis treatment provider with available outcomes. First, hemodialysis patients in the 
US were identified from the United States Renal Data System (USRDS), a claim-based national 
registry of nearly all kidney failure patients in the states. We identified patients who initiated in-





US; were 18 years or older at the time of dialysis initiation; and had Medicare as primary payer. 
Participants were followed from the fourth month (reach stability of Medicare coverage) of 
dialysis initiation (i.e., time of Medicare coverage stability) until deaths, change of kidney failure 
treatment modality (e.g., peritoneal dialysis, kidney transplant), loss of Medicare coverage, or the 
end of study follow-up (Dec 31, 2014). Then, the sub group of USRDS hemodialysis patients 
who were receiving dialysis treatment in the commercial dialysis provider’s facilities was 
identified by linkage of these two databases. HD patients who received dialysis treatment from 
this private dialysis provider and had records on biomarkers of interest were included in the final 
cohort. About one-thirds of the total US kidney failure patients identified from USRDS were 
receiving dialysis treatments at this private provider’s dialysis facilities, and their dialysis 
treatment records, in-center medications history, and routinely measured biomarkers were 
recorded. 
For each included patient, daily records of location (ZIP codes), were constructed based 
on records of dialysis clinic visited during the follow-up period. Patients typically visited dialysis 
clinics every 2 or 3 days. For a date with no dialysis clinic visit, the exposure at the ZIP code of 
the last clinic visited before was assigned. Previous studies have shown that patients in the 
USRDS cohort who received maintenance in-center dialysis have a median travel distance of 5.7 
miles to their dialysis clinics.  
Exposure Assessment and Meteorological Data 
ZIP code-level daily PM2.5 concentration were estimated with a previously described 
prediction model.(115, 159) In brief, this model estimates daily PM2.5 on a 1 km grid for the 
entire continental US by incorporating satellite aerosol optical depth measurements, chemical 





were then converted to population-weighted zip-level estimates using 2010 Census tract 
population values. Daily temperature and relative humidity data were estimated based on records 
from the US National Oceanic and Atmospheric Administration (NOAA). In brief, daily 
temperature and relative humidity from weather station measurements were interpolated to 
census tract centroids and then averaged over tracts to ZIP codes. A patient’s daily record of 
location was linked to an estimate of daily PM2.5 concentration at that ZIP code, as well as an 
estimate of temperature and relative humidity. To assess the possible short-term lagged effect of 
PM2.5 exposure, lag day up to 3 days prior to the date of biomarker measurement were created, 
and associated lag day PM2.5 exposures were assigned. 
Outcome Assessment 
The outcomes of interests were: serum albumin (g/dL), serum ferritin (ng/mL), 
transferrin saturation (TSAT, %), hemoglobin (g/dL), and pre-dialysis blood pressures (mmHg) 
occurred during study follow-up. Among this cohort of patients, serum albumin and hemoglobin 
were measured approximately bi-weekly, ferritin and TSAT were measured approximately every 
month, and blood pressures were measured at the start of every dialysis session. Most (95% or 
more) of the biomarkers included in the analysis were measured on the same day of dialysis 
treatment at a dialysis clinic, and they were linked to the exposure based on date and ZIP code.  
To understand the effect of PM2.5 variation on those biomarkers, we assessed the 
outcomes with two approaches. First, we assessed the change of absolute value associated with 
the shot-term PM2.5 exposure. Then, we defined binary outcome variables by dichotomizing 
values based on clinically meaningful cut-points for biomarkers with an established or widely-
applied clinically meaningful thresholds. Low albumin is defined as albumin level below 3.3 





2000 ng/mL. Low TSAT level is related to iron deficiency and is defined as TSAT level below 
20%. Hemoglobin level is suggested to be maintained over 10 g/dL in dialysis patients, and low 
hemoglobin level is defined as hemoglobin level below 10 g/dL.(97) Blood pressures were not 
dichotomized as there is no consensus on what a clinically meaningful threshold should be for 
hemodialysis patients.(120) In this analysis, pre-dialysis systolic blood pressure (SBP) and pre-
dialysis diastolic blood pressure (DBP) were analyzed as continuous variables, separately. 
Statistical Analysis 
We used a generalized mixed model with random intercept for individual patient to 
estimate the short-term effect of PM2.5 exposure on individual biomarkers’ absolute levels. We 
used generalized estimating equation (GEE) model with cluster of individual patient to assess 
PM2.5 short-term effect on binary outcomes. These two models have been widely applied in 
longitudinal studies. With the mixed model, the change (increase or decrease) of biomarker 
values associated with every 10 µg/m3 increase in PM2.5, together with corresponding 95% 
confidence intervals (95% CIs) were estimated. With the GEE model, the relative risk (RR) 
associated with every 10 µg/m3 increase in PM2.5, were estimated with corresponding 95% 
confidence intervals (95% CIs). To control for potential confounding effect, we controlled for 
both time-varying and -invariant factors. Time-varying factors included daily temperature, 
relative humidity, and time since study beginning. Time-invariant factors included patient’s age 
at dialysis initiation and race. 
For ferritin, TSAT, and hemoglobin analysis, we considered the treatment effect of iron 
supplements (impacting ferritin and TSAT) and erythropoietin (impacting hemoglobin) as 
primary factors that influence the markers levels due to their frequent applications among 





PM2.5 effect we are interested in, we applied a 90-day washout period excluding any ferritin, 
TSAT measurements occurred within 90-day from the last intravenous (IV) iron treatment and 
excluding any hemoglobin measurements occurred within 90-day from the last Epogen 
treatment.  
Sensitivity Analysis 
To assess the lagged-effect of short-term PM2.5 exposure, we performed analyses for 
lagged effect up to 3 days prior of the day when each outcome were measured. The lagged 
effects of prior days’ exposures were assessed in a model that associated lag day 0, 1, 2, and 3 
exposures with the outcome in the same model adjusting for race, age at dialysis initiation, 
relative humidity, temperature and month since study start. The lagged effect was assessed as we 
found persistent PM2.5 exposure health impact across multiple days. 
To assure that the 90-day washout period approach was a reliable way to control for 
potential treatment effect by iron supplements and anemia treatment, we utilized two additional 
methods to exclude or adjust for those treatments. First, we restricted our analysis to 
measurements that occurred before the patient received his or her first-ever treatment (IV iron for 
ferritin and TSAT; Epogen for hemoglobin). In addition, we controlled for the 90-day prior 
treatment history in the model (indicator term for treatment) estimating PM effect and including 
all the measurements available for each outcome in the analysis.  
The data management and statistical analysis were performed using SAS software, 
Version 9.4 (SAS Institute Inc., Cary, NC, USA). The study protocol was reviewed and 
exempted by the Institutional Review Board of the University of North Carolina on Nov 16, 






The final cohort included a total of 173,697 hemodialysis patients with records from this 
private dialysis provider. Between 2008 and 2014, 4.3 million serum albumin, 2.7 million serum 
ferritin, 3.1 million TSAT, 10.7 million hemoglobin, 46.0 million SBP and DBP measurements 
were captured after excluding outliers. 
Table 6-1 displays the study population characteristics. More than half of the participants 
were older than 65 years of age at the initiation of hemodialysis. The average vintage period for 
this cohort was 2.6 (STD=1.7) years, which is the time between dialysis initiation and the end of 
follow-up. Approximately 44% of the study participants were female, and 62.8% were white 
race. Diabetes (48.4%) was the predominant reason of kidney failure. At dialysis initiation, the 
majority (79.5%) of this groups had a vascular access through a catheter. 
The distribution of daily ambient ZIP-code level PM2.5 concentrations for days when each 
biomarker was measured is summarized in Table 6-2. Overall, the daily ZIP-level ambient PM2.5 
averages were 8.4 or 8.5 µg/m3, and the inter-quartile ranges (IQRs) were 5.9 or 6.0 µg/m3. The 
availability and the distribution of absolute values for each biomarker measurements is 
summarized in Table 6-2. 
On the continuous level, exposure to same-day ambient PM2.5 was associated with 
decrease in albumin, hemoglobin, SBP and DBP absolute levels, but increase in ferritin and 
TSAT absolute levels (Table 6-4). In terms of clinical relevance, exposure to same-day ambient 
PM2.5 was associated with low albumin, high ferritin, and low hemoglobin, which are indicators 
of inflammation. Specifically, the relative risk (RR) of low albumin, high ferritin, and low 
hemoglobin was 1.012 (95%CI: 1.008, 1.016), 1.041 (95%CI: 0.990, 1.093), and 1.008 (95%CI: 





6-3). For SBP and DBP, every 10 µg/m3 increase in same-day ambient PM2.5 exposure was 
associated with -0.32 (95%CI: -0.33, -0.31) and -0.14 (95%CI: -0.15, -0.14) mmHg changes in 
blood pressure measurement, respectively.  
The lagged effects assessed were predominantly null for albumin, ferritin, and 
hemoglobin (Table 6-4).). There was some evidence for the possibility of lagged effect for TSAT 
and blood pressures (Table 6-4). However, due to the transient feature of those biomarkers, the 
same-day effect is considered the primary exposure of interest for this study. 
Using different approaches controlling for treatment effects yielded effect estimates in 
the same direction (Table 6-6). Overall, restricting to measurements occurred prior to the first 
treatment ever tended to generate highest effect estimates. There was bias-variance tradeoffs 
observed among estimates from different approaches controlling for the potential medical 
treatment effects. 
DISCUSSION 
We estimated association between short-term PM2.5 exposure, and biomarkers of 
inflammation (serum albumin, ferritin, transferrin saturation, hemoglobin) and pre-dialysis blood 
pressures among US hemodialysis patients between 2008 and 2014. PM2.5 is one of the  
modifiable health risk factors that contribute to 13-125 deaths per 100,000 annually (169), and 
inflammation is one of the three primary mechanisms that link PM2.5 exposure to health 
outcomes in addition to oxidative stress and autonomic nervous system disbalancing. To our 
knowledge, this is the first study assessing PM2.5 exposure’s impact on repeatedly measured 
biomarkers among HD patients. Short-term PM2.5 exposure was associated with increase in 





increased ferritin, and it was also associated with markers of overall health condition changes as 
measured by blood pressures and TSAT.  
Same-day PM2.5 exposure was associated with decrease in absolute serum albumin level 
and increase in the risk of low albumin (<3.3 g/dL). Among renal failure patients, low albumin 
has been linked with systematic inflammation and elevated mortality risk.(88, 89) A recent study 
by Hao et al. reported that peritoneal dialysis patients with albumin levels of < 3.5 g/dL (HR 
15.49, 95% CI 1.74, 137.72) exhibited a higher risk for all-cause mortality than those with serum 
albumin over 4.0 g/dL.(88)  
In our study, we observed a significant increase in serum ferritin level and a non-
significant increase in the risk of extremely high ferritin level associated with same-day PM 
exposure. Previous studies suggests that elevated ferritin is a biomarker of uncontrolled 
inflammation, and high ferritin level has been linked with elevated mortality and CVD risks.(90, 
91, 170, 171) Recent study by Fu et al. reported that high ferritin (>= 100 ug/L) was associated 
with increased risk of all-cause mortality (HR: 3.114, p= 0.021) and CVD-mortality (HR: 9.382, 
p = 0.032) among dialysis patients with systematic inflammation.(30) 
We also observed a decrease in absolute level of hemoglobin and an increase in the risk 
of low-hemoglobin associated with same-day PM2.5 exposure. Low hemoglobin is indicator for 
anemia, and hemoglobin levels have been inversely associated with mortality and hospitalization 
risk.(172-174) In addition, study has linked inflammation with anemia among kidney disease 
patients.(174, 175) Specifically, Chonchol et al. reported that increase plasma high sensitivity C-
reactive protein (marker for inflammation ) are independently associated with anemia among 





Thus, our findings on albumin, ferritin and hemoglobin association with PM exposure 
supports the previously suggested plausible inflammation mechanism of PM2.5 exposure. Our 
findings suggest that inflammation could be responsible for (some of) the previously observed 
elevated mortality and CVD risk associated with PM2.5 exposure among HD patients, and more 
studies are needed to confirm PM2.5 exposure’s impact on inflammation among these patients 
with more or other inflammatory markers such as C-reactive protein (CRP). 
We observed a decrease in both SBP and DBP associated with elevated same-day 
exposure to PM2.5 among the HD patients. Among dialysis patients, studies have linked low 
blood pressure with increased risk of mortality.(176, 177) Chang et al. observed an association 
between lower pre-dialysis SBP and higher risk for all-cause and cardiovascular mortality in a 
cohort of hemodialysis patients.(176) In general population, mixed results have been reported on 
PM2.5’s impact on the absolute level of blood pressures and hypertension.(98, 126) Furthermore, 
blood pressure management goal for dialysis patients remains inconclusive, thus more studies are 
need to assess PM2.5 exposure impact on blood pressures among this population in relevant to 
clinical endpoints (e.g., CVD hospitalization, mortality).  
We also observed an unexpected elevates absolute TSAT level and decreased low TSAT 
risk with elevated same-day PM2.5 exposure. Low TSAT level is an indicator for iron deficiency, 
which is a condition associated with poor health outcomes among dialysis patients. However, 
looking at the lagged effects for lag day 3, it appears that ambient PM2.5 exposure 3 days prior to 
the measurement was associated with significantly increased risk of low TSAT which suggests 
that there could be a lag in PM-TSAT association. Future studies should further assess this 





Our study has some limitations. First, established inflammation biomarkers like CRP was 
not included in this analysis as CRP is not measured regularly among this study population. On 
average, every study patient only had one CRP measurement during follow-up. Second, 
additional treatments (e.g., blood transfusion to raise hemoglobin, antihypertensives for blood 
pressure management) that could conceal PM effect are not controlled or adjusted. However, 
these treatments are not likely to vary with daily variation the ZIP code-level PM2.5 
concentration, and thus, they are not likely to confound the association between PM and 
biomarkers. This may lead to a non-differentiating bias that results in attenuated effect estimates 
because treatment may counteract PM exposure’s adverse effect. Third, exposure 
misclassification is always a concern in studies of environmental exposure as the individual-level 
exposure is not known. Instead, the assumption is made that the average exposure is similar 
across patients within in the same ZIP code area and that the degree of exposure 
misclassification does not vary simultaneously with daily variation in ZIP code-level exposure 
and biomarker levels.  
Our study also has strengths. First, the study population is highly representative of 
hemodialysis patients in the US, with a thirds of nearly HD patients who initiated in-center 
hemodialysis between 2008 and 2014 in the US. Second, linkage of the exposure using the 
dialysis treatment date and ZIP code of dialysis clinic visited enabled the most accurate exposure 
classification we can achieve with the available data, given the fact that almost all biomarkers 
assessed of in this analysis were measured at the dialysis clinic on the day of dialysis session. 
Third, we used a sophisticated model of high spatial and temporal resolution with proven 





longitudinal study design allowed us to assess the PM’s population-level effect over time and 
control for individual level variants by allowing random effects (intercept) for individual patient. 
In conclusion, with this longitudinal study assessing the short-term PM2.5 exposure’s 
impact on regularly measured biomarkers among US HD dialysis 2008-2014, we observed 
changes in biomarkers associated with same-day ZIP code-level ambient PM2.5 exposure. Our 
findings support that inflammation could play an important role in the previously observed 
mortality and CVD risk among HD patients. This is the first study of its kind, and more studies 
are needed to further assess air pollution’s impact on change in biomarker levels. Future studies 
should also study whether and/or how biomarker(s) links PM exposure and clinical health 
endpoints using mediation analysis to provide further insights on PM2.5 exposure’s pathological 
mechanism. In addition, existing claim and clinical data sources should be identified to further 
study the other potential mechanisms of PM2.5 and other environmental health stressors. 
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Table 6-1. Study population baseline characteristics.* 
Characteristics N (%) 
n 173,697 
Female 73,147 (44.1) 
Age at Baseline (year) mean (STD) 63.3 (14.9) 
Age at Baseline categories  
18-44 20,324 (11.7) 
45-64 66,009 (38.0) 
65-74 43,730 (25.2) 
75 and older 43,634 (25.1) 
Vintage** (year) mean (STD) 2.6 (1.7) 
Vintage** (year) categories  
Less than 1 years 51,895 (31.3) 
1 - 2 years 38,097 (23.0) 
2 - 3 years 27,347 (16.5) 
3 - 4 years 20,292 (12.2) 
Over 4 years 28,232 (17.0) 
Access Type  
Arteriovenous Fistula (AVF) 27,950 (16.9) 
Graft 5,368 (3.2) 
Catheter 131,871 (79.5) 
Other 674 (0.4) 
Race  
Black 52,045 (31.4) 
White 104,216 (62.8) 
Other 9,602 (5.8) 
Patient's Primary Reason for kidney failure  
Diabetes 80,291 (48.4) 
Hypertension 50,573(30.5) 
Glomerulonephritis 12,206 (7.4) 
*Characteristics present in this table is summarized based on information collected via form CMS 2728 from 
USRDS database.  
**Vintage is defined as the time between hemodialysis initiation and the end of study follow-up, which is death, 







Table 6-2. Summary of outcome and exposure (ZIP code-level daily PM2.5) distributions in the 










Mean n per patient Mean (std) Median (IQR) 
Albumin (g/dL) 28 3.8 (0.5) 8.4 (5.9) 
Ferritin (ng/mL) 17 681.2 (468.0) 8.4 (6.0) 
TSAT (%) 20 29.9 (14.0) 8.5 (6.0) 
Hemoglobin (g/dL) 66 11.1 (1.3) 8.4 (5.9) 
SBP (mmHg) 266 148.6 (26.8) 8.5 (6.0) 
DBP (mmHg) 266 76.4 (16.4) 8.5 (6.0) 
IQR= interquartile range, TSAT =transferrin saturation, SBP =systolic blood pressure, DBP =diastolic blood 
pressure 
 
Table 6-3. Estimates of association between same-day PM2.5 exposure and clinical outcome 
measurements among in-center hemodialysis patients in the United States, 2008-2014 
Outcomes 
 N of outcome 
measurements Cut-off 
N of binary 
outcome (%) 
Effect per 10 µg/m3 increase 
in PM2.5 
Binary    Relative Risk (95%CI) a 
Albumin 4,341,961 <3.3 g/dL 496,359 (11.4) 1.012 (1.008, 1.016) 
Ferritin c 718,510 
>2000 
ng/mL 
13,520 (1.9) 1.041 (0.990, 1.093) 
TSAT c 816,352 < 20% 196,119 (24.0) 0.979 (0.971, 0.987) 
Hemoglobin d 1,050,118 <10 g/dL 100,880 (9.6) 1.008 (1.004, 1.011) 
Continuous    Absolute Change (95%CI) b 
SBP 45,957,321 NA NA -0.32 (-0.33, -0.31) 
DBP 45,965,168 NA NA -0.14 (-0.15, -0.14) 
a Estimates from GEE models controlling for race, age at dialysis initiation, relative humidity, temperature and time 
since study start; 
b Estimates from Mixed models controlling for race, age at dialysis initiation, relative humidity, temperature and 
time since study start; 
c Number reported here are measurements collected out of 90-day washout period from the last IV iron; 
d Number reported here are measurements collected out of 90-day washout period from the last Epogen treatment; 








Table 6-4. Absolute change in values associated with every 10 µg/m3 increase in same-day 
PM2.5 exposure for albumin, ferritin, TSAT, and hemoglobin. 
Outcome Model a Absolute Change (95% CI) 
Albumin Same Day -0.0028 (-0.0034, -0.0022) 
Ferritin b Same Day 0.14 (0.08, 0.19) 
TSAT b Same Day 2.45 (0.66, 4.25) 
Hemoglobin c Same Day -0.02 (-0.05, 0.02) 
a Same day effect were assessed in mixed effect model that associated the same day PM2.5 with the outcome 
adjusting for race, age at dialysis initiation, relative humidity, temperature and month since study start.  
b For ferritin and TSAT analysis, the 90-day washout period was applied to control for the potential treatment effect 
by IV iron. 
c For hemoglobin analysis, the 90-day washout period was applied to control for the potential treatment effect by 
Epogen. 








Table 6-5. Lagged and same day effect estimates and 95% CI per 10 µg/m3 increase in PM2.5 
exposure. 
Outcome Model Term Effect Estimate (95% CI) 
Binary   Relative Risk 
Albumin Same Day a Lag 0 1.012 (1.008, 1.016) 
 Lagged b Lag 0 1.012 (1.006, 1.018) 
  Lag 1 1.000 (0.994, 1.006) 
  Lag 2 1.005 (0.999, 1.011) 
  Lag 3 0.996 (0.990, 1.002) 
Ferritin c Same Day Lag 0 1.041 (0.990, 1.093) 
 Lagged Lag 0 1.022 (0.962, 1.088) 
  Lag 1 1.019 (0.948, 1.095) 
  Lag 2 1.006 (0.952, 1.069) 
  Lag 3 1.009 (0.952, 1.069) 
TSAT c Same Day Lag 0 0.979 (0.971, 0.987) 
 Lagged Lag 0 0.983 (0.972, 0.994) 
  Lag 1 0.986 (0.972, 1.000) 
  Lag 2 1.002 (0.988, 1.015) 
  Lag 3 1.016 (1.006, 1.027) 
Hemoglobin d Same Day Lag 0 1.008 (1.004, 1.011) 
 Lagged Lag 0 1.008 (1.003, 1.012) 
  Lag 1 1.000 (0.994, 1.006) 
  Lag 2 1.002 (0.996, 1.007) 
  Lag 3 0.998 (0.994, 1.003) 
Continuous   Change 
SBP Same Day Lag 0 -0.32 (-0.33, -0.31) 
 Lagged Lag 0 -0.21 (-0.23, -0.19) 
  Lag 1 -0.25 (-0.27, -0.23) 
  Lag 2 0.07 (0.05, 0.09) 
  Lag 3 0.10 (0.08, 0.12) 
DBP Same Day Lag 0 -0.14 (-0.15, -0.14) 
 Lagged Lag 0 -0.09 (-0.10, -0.08) 
  Lag 1 -0.12 (-0.13, -0.11) 
  Lag 2 0.03 (0.02, 0.04) 
  Lag 3 0.06 (0.05, 0.07) 
a Same day effect were assessed in models that associated the same day PM2.5 with the outcome adjusting for race, 
age at dialysis initiation, relative humidity, temperature and month since study start. 
b The lagged effects of prior days’ exposures were assessed in models that associated lag day 0, 1, 2, and 3 
exposures with the outcome in the same model adjusting for race, age at dialysis initiation, relative humidity, 
temperature and month since study start. 
c For ferritin and TSAT analysis, the 90-day washout period was applied to control for the potential treatment effect 
by IV iron. 
d For hemoglobin analysis, the 90-day washout period was applied to control for the potential treatment effect by 
Epogen. 







Table 6-6. Effect estimates (absolute change in levels with 95% CI) for ferritin, TSAT, and 
hemoglobin by different way of controlling for treatment effect. 
Outcome Approaches to Control for Treatment Effect Absolute Change (95% CI) 
Ferritin 90-day washout period 0.14 (0.08, 0.19) 
 Control for prior 90-day treatment history in the 
model 
0.11 (0.08, 0.13) 
 Restrict to measurements before the first treatment  0.18 (0.09, 0.26) 
TSAT 90-day washout period 2.45 (0.66, 4.25) 
 Control for prior 90-day treatment history in the 
model 
0.43 (-0.35, 1.22) 
 Restrict to measurements before the first treatment  5.44 (1.78, 9.10) 
Hemoglobin 90-day washout period -0.02 (-0.05, 0.02) 
 Control for prior 90-day treatment history in the 
model 
-0.01 (-0.01, 0) 
 Restrict to measurements before the first treatment  -0.01 (-0.02, -0.01) 









CHAPTER 7. DISCUSSION 
 Overall, we observed that elevated short- and long-term ambient PM2.5 exposure was 
associated with elevated risk of CV events, all-cause mortality, and CVD-specific mortality 
among kidney failure patients who were receiving in-center maintenance hemodialysis in the US. 
Among those HD patients, people who started dialysis at an older age appears to be more 
susceptible to PM2.5 health effects (both short- and long-term), and people who had COPD at 
dialysis initiation appears to be more susceptible to PM2.5 long-term health effect. Short-term 
PM2.5 exposure was associated with decrease in serum albumin, increase in serum ferritin, 
increase in transferrin saturation, decrease in hemoglobin, and decrease in both SBP and DBP 
among HD patients, suggesting that the health impact observed in the first 2 Aims could be 
triggered through inflammation pathways. 
STRENGTHS AND LIMITATIONS 
 This dissertation has several strengths. First, the access to USRDS registry and DaVita 
Clinic Research database presents a unique opportunity to evaluate PM2.5 exposure’s health 
impact in a susceptible population of dialysis patients. As the national registry of nearly all 
dialysis patients in the United States, USRDS provides the largest study population that we could 
possibly achieve, which enhances the representativeness of the effect estimates and findings. The 
repeatedly measured biomarkers records from DaVita is also the largest dataset of its kind. 
Besides representativeness of study results, the large sample size also enables me to capture and 





 In addition, it is both time- and cost-effective to conduct a study with existing data. Both 
the USRDS database and the DaVita Clinical Research Database are large health records data 
collected previously. Even though neither USRDS nor DaVita databased were collected 
primarily for the purpose of understanding air pollution’s health impact among dialysis patients, 
with carefully constructed cohort and appropriated study design, this dissertation was able to 
answer the research questions in a time- and cost-efficient manner. 
Furthermore, information from USRDS and DaVita on dialysis clinic visit history enables 
the most accurate exposure classification we can achieve with the available data. In the first two 
aims’ study population, more than half of the included patients had at least one ZIP code-level 
change of location during follow-up. This suggests that taking location changes into account for 
exposure linkage is necessary to avoid exposure misclassification for this population. In addition, 
we used a sophisticated model of high spatial and temporal resolution with proven accuracy to 
estimate the ZIP code-level daily PM2.5 concentrations, which further enhances the accuracy of 
exposure classification (115, 117) 
Last but not least, the individual level statistical analysis and study design applied enables 
us to better control for individual level factors and assess the potential effect measure 
modification by those factors, which is not always feasible in air pollution studies that make use 
of  aggregated level data (e.g., time series analysis on a county level). 
 There are a few limitations with this dissertation. First of all, we relied on pre-collected 
data, and some of the covariates and outcome variables we would like to have access to are not 
available. For instance, in Aim 1 and Aim 2 analyses, we used information on employment status 
at dialysis initiation to classify socio-economic status (SES), which could result in some 





patients’ SES, especially, with a great portion of study cohort retired at baseline. However, this is 
the best information available in our source data. For Aim 3, the established inflammation 
indicator, CRP, was not frequently measured, which stopped us to use it as one of the outcome of 
interest. In addition, exposure misclassification is always a concern in studies of environmental 
exposure as the individual-level exposure is not known. Instead, the assumption is made that the 
average exposure is similar across patients within in the same ZIP code area and that the degree 
of exposure misclassification does not vary simultaneously with daily variation in ZIP code-level 
exposure and outcomes. This potential exposure misclassification is likely lead to non-
differential bias. In addition, for all three aims, we started follow-up after three-month of dialysis 
initiation to achieve Medicare coverage stability, which is a common practice with this dataset. 
However, this could lead to selection bias and could result in attenuated effect estimates since the 
mortality and other health condition were known to be higher in the first three months of dialysis 
initiation.(178) Finally, for all observational studies there is the possibility of unmeasured 
confounding. In this study, some of the known potential unmeasured confounders are physical 
activities and forecasted weather. In the presence of unmeasured confounding, our results could 
not be interpreted as causal. 
PUBLIC HEALTH SIGNIFICANCE 
The findings of this dissertation support the conclusion that particulate matter exposure is 
associated with elevated health hazard among dialysis patients. The ZIP code-level PM2.5 
concentrations observed for the majority of the included person-days in this project were below 
the current NAAQ regulatory standards (both daily and annual-average). In the United States, 
ambient PM2.5 concentration has been decreasing on the national level in the past decades. 





2018.(149) However, the PM concentration in many highly-populated urban areas still exceeds 
the NAAQS standard, and extreme events like wildfires also lead to high exposures.(167) Our 
findings suggest that lowering the ambient PM2.5 concentration on the individual-level could be 
beneficial to dialysis patients and other at risk fragile populations. In addition, both the short- 
and long-term exposure to PM2.5 have been linked with elevated adverse health outcomes among 
HD patients. This suggests a dialysis patient could still experience PM2.5 related health risk from 
elevated exposure they experienced years ago, even when they recently moved to an area with 
lower PM2.5 concentration or the PM2.5 concentration of his or her residential area was lowered 
recently. Last but not least, special care and guidance should be provided for dialysis patients 
who initiated HD at an older age or/and with COPD as they could be particularly vulnerable 
towards PM2.5 health impact. 
FUTURE DIRECTIONS 
 Our study also lead to several future directions. Aim 1 and Aim 2 analyses demonstrated 
that ambient PM2.5 exposure negatively impact dialysis patient health conditions. More studies 
are needed to conclude on whether and how dialysis patients are more susceptible to PM2.5 
exposure comparing to the general population. In addition, within dialysis patients, further 
stratification analysis could be done to identify whose health is further impaired by this 
ubiquitous pollutant. 
 Aim 3 results linked PM2.5 exposure to change in biomarkers for health conditions and 
inflammation. Future studies should be conducted to test the potential non-linear exposure-
response association between PM2.5 exposure and those biomarkers to further understand PM2.5’s 
pre-clinical effect. Mediation studies could be conducted to sort out how one (or multiple) 





mortality). In addition, Aim 3 analysis reveals that some treatments could potentially mask PM2.5 
effect. There is also the possibility that PM2.5 exposure modifies the treatment effect of 
medications or procedures, which could and should be assessed in future studies with such rich 
information on treatment history and outcomes from USRDS and DaVita Clinical Research 
databases. In addition, with such dataset and other existing claim and clinical databases, other 
proposed mechanisms (e.g., oxidative stress) of PM2.5 toxicity should be studied if possible. 
FINAL CONCLUSION 
 The results of this dissertation demonstrate the adverse health impact of ambient PM2.5 
exposure and link PM2.5 exposure with inflammation among kidney failure patients relying on 
maintenance in-center dialysis. These findings suggest more studies are needed to develop and 
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